var title_f2_3_2096="Direct US IV placement";
var content_f2_3_2096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Femoral vein catheter placement under direct ultrasound guidance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Operator inserting a needle into the common femoral vein under direct ultrasound guidance. A transverse position of the transducer in relation to the vein is recommended so that the operator can see the needle tip enter the center of the vein lumen. With a longitudinal approach, the entire needle course is seen in one image, but it is possible to be at or near the side wall of the vessel without realizing it.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lauren W Averill, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2096=[""].join("\n");
var outline_f2_3_2096=null;
var title_f2_3_2097="Nasal polyposis";
var content_f2_3_2097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasal polyposis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 389px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGFAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Yd23t8x6nvTd7f3j+dTSRqGY5PJPSm+WPegCPe394/nRvb+8fzqTYvqaPLUDnNAEe9v7x/Oje394/nUvlp1yaPKUdzQBFvb+8fzo3t/eP51L5S+tHlL6mgCLe394/nRvb+8fzqXy19TSCNT3NAWI97f3j+dG9v7x/OpTGg/iNBiXnk0BYi3t/eP50b2/vH86kMa+poMa56nFA7Ee9v7x/Oje394/nUhRAeSakgtJJ2CxI5Y+1A1FvYr72/vH86N7f3j+ddPZ+FHZA15OIwRnC8mrS+GrFTgvM3uTis3UijaOFqS6HHb2/vH86N7f3j+ddj/wjtgenmf99Uf8I7YEDHm+/wA1HtYlfU6hx29v7x/Oje394/nXY/8ACOWP/Tb8WpT4cse3m/8AfVHtYh9TqHG72/vH86N7f3j+ddj/AMI5Y/8ATX2y1KPDlj3EuT6PR7SIvqlQ43e394/nRvb+8fzrsT4csexk+m6on8P2QJCmTOO7Ue0QfVKhye9v7x/Oje394/nXaxeGbAgbvOJP+1VyPwnppPzLOfpJj+lL20TRYCszz7e394/nRvb+8fzr02DwXo753C5B/wCuo/wqVfAmkEjcLvB9JR/hR7aI/wCzq3Y8t3t/eP50b2/vH869WbwDoqsoP2znuJh/8TTz4B0IYy19+Ey//E0e2iH9nV+x5Nvb+8fzo3t/eP516z/wr/ReCPtuP+uy/wDxNOPw+0MOFY34B7+cv/xFP2sR/wBm1+x5Jvb+8fzo3t/eP5164fh3omTg3/tmZef/ABypI/hvorx7s3/085f/AImj2sQ/s2v2PH97f3j+dG9v7x/OvXpfhzoZQBZryJj0LuCP5Vg6t8NrmBGksJvPQc4OMmmqkWRPAVoK7R5/vb+8fzo3t/eP51bv9NubGQpcROhHqKrhUPQnPuau5yuLi7MZvb+8fzo3t/eP50/YvqaNi55JoFYZvb+8fzo3t/eP507auOpzQFX3NAhu9v7x/Oje394/nTto96No9TQA3e394/nRvb+8fzp21fem7RQAb2/vH86N7f3j+dLtFJge9ABvb+8fzo3t/eP50uBRge9ACb2/vH86cjtvX5j1Hem4FORRvX6igB0n32+tJTn++31pKkA70H3oxijt3zQAuPypCKXv7UYGaAE60Y70uKX6UANxmlx6A0uKAPWgBuPXg0vXrSgetEaNLIEiUsx4AouNJsb0FS29vNcPshRmPsK6jRvBlzMnn3xEMQ7dzW/Fb21kClpFtPQtis5VUtEdtHBylrI5zTfDOAH1Bio/ug81vW8UVqm22jVABjOOaeUJYZ5/WpvLAQe/pWEqjZ6EKMaexAVZm+bLAj6Uvl/Lnip1jPoc9qekeSCQBioLK3lH8KBHuUZBq2EOOvWnRwhvXd6VaQin5RwOmKAh46g/StBoNrdPypjRYzwM/WqtYTZSdBnnmk2cZOcfSrbRkHoAfSomXBzyf5UmyRlnGkt/BFM4SNmAZiRwKn8Q6QNM1AmKUTWDj93Mozz6VXKBsghfYipra4ltGMRYvAw+4R0olPSw4p3HW9qzQxsmSD3FaK2sgljXafmxg1DYEnITAU84LVuW1xuRFdVOzgEDpWd0dkW0hrWk0EkaPG2W6EDrVuCEszgo25RzkdK37eBrmCJrf5mUhwPTFWJbiNblJPLco3Eg71VkNTOXCh+o6Gm7G384wegrcuNIZvOntgVjByoPYHtVaOzlkZVKYc8DNS4s6I2K0UGYieMUSRZTuPxrRltpbQtBMhjkAz0quI2Jy4Jx+tJ3BIiiTepJBBFSrthQKckHvVq1jQqwIAHXNJJEJB1BU+hppitcqXVv5luSqE1FpSSKmNx47HtWlCuRsIXFV4gbaVlbG1uMCmXbSxXvrGw1VHhvoF6feArzLxX8P2tXMmlMZE67eteqXMZ35HIb3qh5bi4LFsY7daXtZRZz1cFCqtT5+u7W4s5NlxE6EeoqH3Br6J1Lw/p+v2nlXMaxy/3hXlXi34f32il5oAZYByMcnFdMKqkeHicBOk7rVHFfnSHHOKd0OG4PvRtPetTz7WG0lOwaMcUCG0H60tGMigBCaKKKYBSUUUCCnJ99frTadH99frQA+Q/O31pPrTpB87YHc02kMBijHPej6daX60AL75pD04p2RmkxSATnNLS0dRTATHNBIAJOBQxC11PgvwZe+IrpWKMtuOS2O1JtLVmtOnKo7RMPR9IvNYnEdpGxBOM44r1nw/4MstDgWS9RZbojOGORXWaZpVl4esxb2caNPjDSEdKiuFLks5yx6muSpWvoj2cPg401d7mDq8ryLkfKgGAo4A/Kue2c+pNdBqaAAqNxBrKaPDj0+tZI6WQxQ5fGPyqw8XzgZNTWsYO49fTIqxHAXBY8Ae9UQygsOemc1KIeO5/Cr0cIweufQCrdvZ71Qt8oLcfStEjJszIbVpYppFGBFjPNWrW3RPLkfBVlIPFWbH919ugVQY5Tj1pqoQgX04HFVfsRqypPETJnjjpUDx4Q5xWi2Mc43AVVmGV5xkipcikjPdcZ6kVXfljzwOelWpARjP8AhUAXf0HU81DZdiIZKMR0A7VHgN2PNT3I8t0A6d6YiE88c+tZtmtOJZsTsb29T3rchXcgJ7/hWPaLhjxnHTNbMILJjgEc9cVCkdSibOlXb20RUHaT0Oa17e6UxkvnfvBAxxWFavgqc9vSrjZikGOS3oOlaKQOl2N7Vbto8vbBVB7Lxmorq7+2/Z5FGx4wN2KpO0jRgMTxTlxgLjg+lPnKjTLmtztfzxTFduECj0IFZ7oCpAxmrkIBj2gcKeKiEDG4ycYxn1pcxqoleGLClCOTSRoYSw44q6y/P34qJ0OSaOYpRKqszSE9PpRPExjzknFTeWVJIGKcBtj+fnmlzF8tiAIzqCAMAVC9uCxGP1q9HJuO1B1qWG3JJJ659KNxbFKCJ43BxkVpKiPEVuVEiNwQwzU3lqCPl6U6RN64XAP0q0rbGUoqR5l48+G0N1C1/oo2t1Kf/Wrxq7tp7GdorlCrA45r6yRXWIAYGeoIrmPF3ga18SWreUBFdqMjHc10QqdGeTi8vUlzQ3Pm7B69qQjmtbxFoF74evGgvImAycMRgGsvIK8c1ueFKDg7MYaTinY9KbQQJRS0lABSUtFMQUqffX60lKn31+tAEj/6xunWkFOkzvbnvSAUhiHv2pQPeijtSADS9aWigAprNtHv2FK7bRk8+1egfCvwBc+Jb+O5uUZbRTkkg8+9DaSuzWlTdSXKhvw2+H93r94lzdKUtwc/MMcV7n9mtdJsvsWmLtjAwzY5NazQ22lWSWOnKEiUYZwOTWRcdec1w1Krkz6DD4aNKJnyIMdByOe9UJxwflNasqZHXH0qpKoAJYmsjdo5jUlHmBc/N9elZ5jHPHfGavaiSbojoPpVbb8wGOlWtiB1rGTujHOfetFo9kJQAAKKh0+PlpNoAzipZpAVkYEYzRGWpDi2bGnQ2jeFLu/Yfv0fysfXvWcJT9mgjQAbc8g1PBcGLw1JbKzBJJAxB5qoGG4BeqjkCtXO5ioN7kaAICB/F1pGbgdvwp8mNw7kVG+AMfzqXIrlISxJB/Piq8rYzx2qSWUCMjODWbLIMkk5A4qHItQEchm25x2p8MLOcDPHep9Ns2mk3HhevIrWFssf3encVLZXKYV7bN5fzHOPU1BAAR1x9a3b+PMJcAY6dKzY7cygiIHcv4VFzWCCJSp3Yz2rUtSMZIHIx9Kz4RiOQSYDg4x3q5bk7MAciobOqCNa23LgH6dK0YV8y4G4jjseazIH3KoA+Ye9aKv5cgfgkjtTUjXkL5YOr4OCKbZL5kgVuce9NTCxlcHc/P0qxYDY6sB0Oad7jULCzxtayeW6kNUsfzYwOcU66Lzu08g3dhmpLdNiljwaEy+QikUZxnnvmkWIbT3/ABqZtv7yTPAHNU0uVYEZPNVcpQEZOOfqKjDIEYMRk1dePcynjpxUDWLOXOSAaW5cYrqUtJkEl06nsT2rVuXWLbswfXimadYGMkkc+tXxAA3zKCTVJESirlUyF4/lHOKkswxPzngdana28pSQOp9elIQoU4Az3qkQ4roPdEKcH3yKSJlWTerYYUjRloDgHkVR06OX7QQ3T0NWmyXTuibxR4dsfFOmmK4jj+0KPlYjnNfMPi7w1eeHNSlimjbyg3ytjg19bwwMsWVOGz1FVPEXhSy8V6ZLBdRqLgD5W7k10U523PKxuCjUjdbnxxgMuVpDwcGuj8deFbvwrq8kEyN5WflbHGK53O4ZB4rY+bnBwdmMNJTqTtTIG0lOpKYgp0f31+oplOT76/WgZNIf3jfWm/ypXPztx3NJzUgFLQKWgAJ5oLBRkilOO3Sr3hzR7jxDrENlaoxDMNxA6CgqMXJ2Ru/DXwdc+LdajXY32dW+YkZBr6rtbG28PaVHp1iqgquHZRjNM8G+G7bwb4eigijQXbKNxA5FOuSzElieea4q9XmdkfQ4LDKnG5mzrkE4FZk4zICRx2rUmUgE849zVCVM57n8qwR3NFNxkEZqnf8AywnI5I4zV8rnk9qzdVOCOopMixyl2CfmUZy2M0qrkr8o9KsTx/vG6YzxU9tDuuBxwOeKpPQmQiQqkDDp9PWqYjYrzuYZ71qvExZl6pn6GmeWIiFGMGs3LUqMdClMf3DAgbQM4rDfUmM3yZUN8tdJNCrmUHG1hg1yM1qImmU/eQ8HOah1Hc2p0k0dGM7UAJJxnikuDtAwMg96w9PuX81QW68Vs3BUR8NwOcZrRVLoxnRcWZ1/OqKR3qvBC9wjEE+vSqU07T3kinKotdvY6bPYWFjPeQPFb3QzHIfusP6VUbvUmceVGvrWnWOmz6Z/Z0ry29xZrI+7+GTvVHyDywHyj2q6q7sQt0T7uaSRWx04pydzOKsZF9GVGADgdaythjkypIz3zW/dgPDID3rDZCu1cjO4DkdqzNYj4Yldy0jEdSeOTT4VxGS3U1bea1t7m5jtg8g8vaGb17kVXji81EIIJHXmkzqpsuQr86kDA6EVpuoIVto44FZ2SVQLxzg8Vrou5doAJxUHUkXbeIbVYqN2OamhUFzgGlhAEXIyRUttERkMOvvVIpIsIgaIAAECmzLuyq9BU0aZUBPxqJiVlxg8U2VFFO6RvsjZIVfWsSynCSfOQQD3rZ1+R3tTHGCenNYNvasWXqozmo5nex1KF43Z0oPnKuzgULJiXyz1+tWLK3EdsMnk80W9uDclmrVIwaRet0G0HsevFTPHt5FTQRhEBOMmmzuBnAya2toc+7IZQCpNZDSlbxlPJ7DHWtJXY5BBrO+zO18HxxnArPW5oo6G9bQAwrkZBHQ1W+yFLpWQADPpWnbjEaqanCqDknmumMdDlc7aDVQGPB602M+WSQcN2PSpgc8CmSQEr161XKZ+pz3j/wANWfi3Q5VeIG7RcqQOtfI2vaVcaJqU1rdROgViBkV9qwRyI+4dc1xPxc+H0HiDSJL+zjAuUGWCitqbezPKx+EUlzR3PlFsY46Uw1PdW8tldSW1wpDocc1CRjrWh8+1bQbSUtIaBBSx/wCsX6ikpY/vr9aYiVx+8bHrRSv99vqaSpGKAMZyM+lABJ4ooJCqSRQAjBndYY1JdjgAdTX1P8BvAceg6ONX1GMG4kG5AR3ryf4CeCH8TeI0vblM2kBzyK+rr7Yix21uAsMQ2gDpWVaVlY9TA0LvmZnXsjSuzvnJrKnGTxn8a0rnpjPNZ7jHB615zep78VZaFG4HReeapyLkEk57CrtwfnHf3xVZ+FPuapMTRQkXbnpism9G7J/rWtcHIIAGTWbdIQpJ4A56UmSznpU3ElgMk9jV+yh2o77QSBioJUbcCRjnOK07KPdaPnOSafQyluRBSFJPT1qs43vtI57GroiICqxOM1HLFsmUY5Y1kzSJXiiIbsM1l3tgBehlXKt94GugjiG1mx06ZNRyQEq25dp7d6hq5anbY4zUtKaC9SaJP3RxnHarrWzkeUSTGw+8TXQyw/IA33T2NUpYiGYc47UJF+05jjmsTa3LqwJ+bI9xXoGm+MJo9FvtEvYUuLCeMeQW/wCWLD0rIliW4UpMo3gcH1rKRhDJslxgHtWkZuOhnUpxqas6+ycXECyKw3KMHipHJKn5xx1rndOvPs8m5CWUdQa3JJFeFZIjnIyaq9zNxsQTA7CrEZ+lYrttmm3dV7GtWSclmznHqO9YczEXDM3AYZ5qSo7j7cBon6eZ9761NasU3YBxSWzxNACQAWGOKb/q35YYU45FSzrgakCmQJkAHr9a3LRSH3EYyOOaw7dgWyD8vpW/GcJGQfl60kdMUX4Y/n7njpVxUAGB096rWsgY5PH1qwrbUb3oUrFpFkMuBg/KOKjulGQVxjvUCbsYNXIowVHHJpptjtykTxI8Y3Dr61XktkRgwGPatVbb5Mmq9yhA+Xr2q7Mcal9BsbD5VIxVhYhvDCq1qrsfn7dK0beMY56VpFETdiJvMYgA4ANTFPk5qXaBUUr7sqvUVTMb32ICVVvarMUKkhgOapSwseTmtCz+4oNKK1HPRaFtY8ID3qGTLMACRV1SAuKr8F811dDljIWOM4BNTBux7UKwNP2Dr60JXIb7jMgDpzVmylAYo4zG/BBqq5IOAamXAXtVLRkzV1Y8A/aE8AfZJzq+nxjy2+ZseleEId6HPWvu/VrGHXtIuNPulDblO0mvjHx74dl8NeIZ7dkIi3HbkfpW97nz+Ow7g+ZHONim09himGg84KWP76/UUlKn31+opiJpP9Y31NIOO1LJ99vTNIKkY6pLGzm1PUbeyt13SSNtFQu2FJINe0fszeDTrPiE6rdR5t7flSaZpShzyse+/DTwzD4R8G20CxhLmVAWPetWVeea07+TzJyF4VeBVCYcDFctbU+hw8eVGZcjngfjVGZTg4rRlXcRVK5XsO9cbO+Jlyj5jk1XdSRyTj0xV6WMjJZce5qtKoCnkn6UIJIypAS/sDVK6HB4IGMVpeXgEnrVC84zkj6GhkMyJ4/lyDnHPStKyXNnz69qobtxcYwK0tNIFopZS4RslT3qlqjFrUWWEBlB/Oqzxu0qONuxKuXUol3MqhQTwAelPjjwF44NZtFp2K0SDZk9CeMU6RAV2jmpoYSUdS3Q8e1M2tvAA/EipHYrGMeWV25x0NU5otynjDA1svDlSvv1zVUx4kI6djxVWBaGNLEGBIIDr0rC1JBMC3Ruhya6+aIb+AM9KwNRgO04U9896zkrGsGchJeyWtwu0ZHvXR2F8JIgUY7G6rnpXM6mqmQZABJxTtLk8q52k8NwOelJM0nTurnYM+Y8Kc555rIu5MzY74xzUvnPER5vTpms67k824PkPyozWvQ54rUuW6hVjBcZzjAq20e+4fBO3b+tQRMj+XNzyOfTNXJFEYLL0POKzZ2QZY0w4wC1dDEuYQDnHua5rTG4LuAMnArqbQboACB071B0xNC1RcZParRDEcAY+tNgQbBjucU+4cBgoplrVkiL8y4Par0C/P7VXtSBHk9atx4Az2rSCsZzY+SVQmO47CoUG9ssOKay5lzzirDDanArZEaLYZtUHipoiOgqK3BOd2alCkSe1VexMuxLjnpTAiiQmkeTnA60Jnbk9ab1IsxJSM81LD0yOlU5iQwJ6VoWoBAOOlEdxz0RKgJz6U1ht4FWkUYpJUAOeM10qOhzc2pWXOPSrUTblHqKYAPwqWNBjinFCkxjJk1IiErTHOKWCX5sGr2ZLvYazGIhh1FeYfHnwmmt6ONStowJUGWIHevVbiLepI+tFtZx3dnPZ3HMcqkYNNLUwrwjUp6nwLhlLI+QynBpprt/i74afw34snUIVhkYkcYriW/nVnzFSDhJxY2lT76/WkpU++v1pmZLJ99vqaAc45pJMb2+tC8VIxyxNc3UVvFy0jBR9TxX3P8ACLw6nhbwFbR7dtxMoJOOa+Uvgb4dbxH49s0K5ihYO3FfbupBYgkEYwkahRim9Ed2Ehf5maxyeagmHHapyeeagl5rlmrntQKTjBqjcckjrir8vGaoSnLH3rkmdcCnISv3TnPrVWQbixx19qsTDJ6dKjAznPAFSjRopTR4XOPwNTaFodpqtveT6hLJGkZ2pgY5pl2B5ZFaVhcJaeCCzOwkaU5woJ61rFJo5qza2OBmiijuZ44HMkasVU45rrfh5p9tqurpp92fkZS3HfHas7XLZLHWYzlpUmQSYdQp5HtWj4EkEHiqzkUEAyFfwNdOFaUrMwrSl7NuO56Frnw/0F7ZMS/Y3XgOW4yfauA8V+Hrrwu1utxIJbaUlVmHHPoRXezeEl8R3N9Nd39yiibbGinGzHfFaXxF8Pya14YW1twZLiFlZCepIrrr0YSVk7s82jipQqKMpXR4/wDZzDAJHztcZzRFEO2MVe+w3jytZXEbK0IwwaolV0bAHzg4IrxpR5XZntJ3WhBLb5wVJz6VQmTMhyCO/St1EdlLMRu7DFUJFLHDYznFCEY999wuCfUGqNyscmduOVzgetat7BtbEi/KvSqBtlZBIgww6H2pSWhrGxwOsWmJQXGNxwD6GspVYSFHGCp45rttWtjM7kGMbOQCcVlSWMd8qSs4hRR+8cDJrnbsdUXpqLp11Hc2i2s5zMThcDJNVYootO1GeO5WQHacBuKm8P3z2OoefpRWSWIFQ06A4z3xUWvy31zcNdX773kblgABn8KrmsjNQTkWdLh32MhxzuyA3pV5/L+xA+Y3mgZwRx+dHhu2kbTbgzbhjAGfSlv4gIVTkYPXNN3sWrXsSaY0RtGaSRhLn5UUcV1Gl/vkVs8YrlLKPYm3Izng46V0mjOBF5YJ4Pc1mdETbVt6/Kc4qWBQ02CKgtwVDIfqatxjy493GTVo26E4H8I5x71MrNgA8VTicLJljxV1fmrWLuZyQ+N179akLbl4qCNMTAnpVkEB8dqtMyla46H1anyDJG3+VOjiyQfWrHlbRwK0MZSVzMMbeeOTirMp2qOtMkXEgNLId64qGW3exXuc7QRVi0kPlj1pnlbuDUqIEApxTuEmmrGhFJleaHcZFVI2ycCrAAIya6OeyOZxsx4bI4qaMHtUKMD07VZTBAq4PmZnLQjkXNII9vNWUQE8U5146VvYjn6EMTZGO1TI/lsCOMVEiYJpk5Ixg00hNJux5j+0f4ZXVfD66nbpmWIZOBXykCduD1HFfeepWqavoN5YSqG3IcZ9a+IfFentpXiK9tWXaFkOB7U73PEzCjyPmMk9aE++v1pD1pU/1i/UUzzSSQfvG+tI3CHvSv8AfP1oEZmniiX7zsFAx3NIEfU37JHh4Q6ddavIg3NnaxH+e1e4XZ3u7HqaxPhLpC6H8OrGFRhpEBNbsg61co6HrYdWMxwc1DIevtWg8eeapzLz6VyziejCVyjMAaoyjk1oSCqcoP1ya4pnZBlCRM1G67QO+e2KuFee1V5l3enHpWZo3coXIHlHIBBFLd6rph8K/YJLSUXu7hx0z69afOMJg/hWNfru29Dg1UZtaGFSmpbjvEGpyakloshB8mMAkcc0/wAPOIdStJmYhUlUk+2azMBmYfhVu1U27Rsw3Rk9K3pVOV3MpQTjyntdxrOlw+J7UDUFSSaEqUDcexNdJGpkaOWO5LR46DBDV4FdQoL0SquCVHJ6itS31zVbSAwW160aHoAM12LE05LV6nmVMsulyM3PFZt5fFt1PLc7YYUVdidWbqa5balzNJPDuUSNkc9BTbeDcGd8vI+SzN3NLpa4gZVycEjivOqz55XPUpU/ZwUb7D9rruBIOKqXa7Jc88gYxWm4AUED3qO8QCzLYXcOahFGFcksD5jZzx71SkVeAMfQ1eCEqCR1OaimiXlmPI6U2UjntUty6t8gNYljCVgdCmBnFdXqCExux5AGKwra32pIAcYOR71zSWp0KVkc28J03VcEExvyO1b1/CLvRJUXBZRvWq+rW4uLfeud6c1PpB3tGp4Drg96cUKT1TCOcmxsL5DtjChJl+lT6uEaISR8q4BFVNPhcJqmmufnXLL9DUtiUl09oA24wLgk+tVfoaJdREfa8Z9VrW0QsHY7iCDjPrWDBKC6h1wVPXpW9pzGKQ56E8CsmdMDpkdiqgA/N3q4FJXrwtUlQgJ7jNXICwQsec9qpGxWYk3ChcjPUVpIzKygc561XMQVSRjdnk1bi4QDHNOKJm7k7KWIx1pwQ5FNh3MePzq3HGScHiuiKuc0pWJYiFIqwTkcd6rxIFOSQalkY7eK0SOaW5VnwHwO9Pih3CpYoQ7gk1ZYCNRxVKOo5TtoioYcCo5F4rRjAfk1BcIA2Kpx6kxqa2KcYxzStKelWWT91gdarGP5zUtXNE09xsbvvByQK17Y7kHFZsaZOK0rcgDnrWtLQyrO+xZAKim7s1I/zJxTY0yDmunmOS/ciPAJzUL5birbJio41GarYuMrakVqDHOp7Gvmf9pTw9/Z3iNL+NcRz+gr6iaMAZFebftF6MNT8D/alTLwc5xzSRyY1e0gfIJpE++v1oHK0qffX61SPniR/wDWN9a3PAOnnVPGemWqjIMoJwPSsNz87dOteo/s1aZ/aPxIt2K5EQz9Of8A61ES6avJH2qtsLTS7O2QYEcYGPwqpIvPSte+GZcDsMVTkjrZ7HpUpWRnuOKpyr1rRlWqc4rlq6I66bMqdeTVOUcjitGcDNUJRzx1rz5HoU3crPgduart6YzVmTrURXPNZGyKNwOAM81jzrmQrwQa27lTk9KxrsEtndjBpX1JZlsCjNxV5yPs8Y96iuk2uvv3pesIXqRzWkWZNGrc/Nb28meg5p8Y3/OnIFO0799blGwwHI5psDeVcPhSE7Y7VLBFiErw7YIIx9KjsFVFm2nB35+tTYBcOMMfbpVG2VUvJn3AKDwM96kpLQuy5DBAAQeSPSoblg2N3QcdasIpYszcZ9aZJEuw9DVEmdGgjhYds81Um+dWKngelXXi8zaF4A64qtdx7Y/3YPJwRim2UrXMO5DbsN8yMD96qESYd0GOOa17xeRtB469qzwuZzzg+lYPctszLlTuKgYz27Vm2TGGbA6oa3NQjyigdT7VjFQl4wfB3L9OaWzHuie5ujY6/b3XyslxHscU3w+gM19ICFWR8bfSquq7ZDpoc/Ks4BGc8VtwxxfbLloiEQ8YA6e9CV2bprlMy6jK3LJkDPI4rVs2LiMKcnPJrP1If6QOGP8AdOat6VICzA5+XrUy0NYO52JYIi46ADJoNyN6KgOfaobJTJtL/dIzVyCJRJkDjNLV7HSmktS5AMwFn+9UsRyoOO9SmMADjj2qWKJSgwK2SOdzRLb43Yq7MmApU81nxRkS5z+FakUqwkGQBh71vT8zlq6O6KapucnNTLycZprlWmLKMKe1OAGQRWjdhNjgQjehqUfPmqs6sCKdCWUD3pxdiXG6uWkbb9ahchmp/Q81WYkSZpt6CitSx0FQyEUrkleKhKt3zU6lRRNF9KsKeetVYgyn/wCtUm7FWmKSuakRylPjIziqts+VxU6HBrojqjkkiaRSVzUKnB5qYtxUL4q27omPYUtk4HSqniayGqeEdRtnGf3ZIH4VNGCXNaNqgkjmiYcOpFJPWxFZe6fnpqEBtdRuoDwY5GX8jVdPvr9a6r4o2H9m+O9UgxgGQsPxrlU/1i/UVoj52ceWTQ+Q/O31NfQX7HNgJvFN9ckD92oGfw/+vXz5L95/XJr6k/Yst/l1abHfH8qaCGmp9J3AzOx96ryrxVuUZkY+9QSjit0dkHsZ0oqjcCtGYdc1n3A4rkrnbTZmTfeqpOvNXpFJIqCaPArz5anoQlYzJlOQaYBxjGD61akTtjiogpArNqx0Jmdf52Y456ZrHcbm2vwK3bxfY49qyp0JboSpqOpT2KF2n7pT/d4OBUNq2ZSp6EdKuTRnY6HHqDWdDxOpJq4mLRr6TMI7nyjxnoavyL5U5GeG9qxo3InV1GdpradzMgCHDgelEkStGVZIzNMdrNGOhxTYbbafmUYz97PWrkYBysg3HrTSoUtEvBHIqLmiYkkjoQGB2EYyKSXaq5DjHU4qWEZ3BySPSobu3jeEBEAZj16U7kkkKxi0wAVlznP96qNwpaV+QOOgFb8l6lxbqBGqPENvFYdxFuMjMxVvUUMUNdzDlAMTtnnNUBEftG/qcZ6VpSx7bJgvODkE1UADLvx9DWZozOvlLHBzk1j3aZuo25G3IPNbt4is27aeBnrWXKA/GehzUgmc/qz5ktYgxUtKCSOa6q4gSJsWwZgBncR1NcyWWfxNbI8iiOI5Y12Bb98zAlkrSEbmkpW0MS9uC0SjALg8mpbEYuUOR8+Q3FU9VZIHlClj6ArUtuzM8RAYbSCeegqJI2pyO4sEBTg8AetaFuMyAgZUd6zNPlzbN6Yq2jsIgqg4PeoWh0rVG/FzHk4NRwSncU9+tRWZzbhQc1OsZ61utTBruTBgG461IWLgZqJMDrUmc89q0i7GbHD07etWE2oAMdaqqxZsdvWppHyBjoKq5EkEkucgdaltl4ye1QquWzipgSpAWmTLayHzEZ461EELNyKU5zmpMgc07krQaqBRSNgA0rnApADsoTASNgeM81K0dVUBD/jVtm+X3q4sJaPQktTgkVK7barRnmpHORWqkZSWpMsmVprvhsUxDgetRyZDCqvoJR1LkPPOc1oWTfvgPWs+3GUzVy0O2ZT+FOG9znqrRnyL+0rYfZPH7yAYEq5/z+deUL/rF+or3z9rK3C69ZTAfeHX8K8DX76/UVujwMQrVGOl6t6ZNfW/7Fyf8SHVH/28frXyPIMs/wBTX13+xcQfDmqgHkSc/nTRlHqfQT/eNMccU9x85pkh4rY6kZ9yvJrOkXPGK1ZF3Zqu8GT0rGpG51052Mtoj6VVuEwK2ZIcDis26XBIrhnCx106l2ZEg+ao8cc1ZkXBNQsK55Hcnco3gBFZMmcE56VsXIznNZEo+fAxj3rLqarYoyj5twOCOtZzgAkjtWxOuOe2OazZoyHyMc9qaIY+HhCCBuI6itG0kKpGwPHRqyHZkC46dK09Kkw4RhlDWiVzOXc0nTcQCcjqppjndKrYOU6gVYMang9uBUPzedtXAI4PvWLVhp3FB8uU5yVbkUsZEk+7og6DHemxp5iMrjcQalEe1Qq8Ci4ECN5cTgjksTjFV5eYX55Jq3MVQmTHIGBmqbhlh3cE55pXGjHbmBk7Fqqj5VMbAEDlTmrco2sOmw5B+tQzH5kUAZwcmgpmbMQUcgZIBrEuCQjMSAAuc4reuMbyMHGPpXO6oSbV40IBf5RmpSuxXsig9tCZgLV1mj27ppF/ib0+grorZiIYSp2gD1zmuc0rMCtGwA28H3Fa0H7uI/NlN2QPaupRsiea+5V1NvOaQsCGJwcDpUMbZfbkcqO/cVJqKhVDRrtRuD71Vh+WdVfg8g1lJG8Jana6FN5kQB+Ye3NdBF+8AGCB2rldDk57IAO3U119ltaMEMNornR3J6Fm3bYAuMD1q7uAVQB1NYrTH7UBjKeorVickAL0961gzOcepNjLc9akwfLAApsUR8ws1S5AfA6VtExkxiDA6USNgc1MPuYxVeUgjgU2hLVliF1xml8wE5qrbxlgQeKspERwaUSZJJjy2VzSRZbrUnl4ApY1weBVkXVhGTGKXPGKkdOeaifg1ViU7iqnOe9I3pUqnIo2jrVRFfUIRke9S7QBzTUOBgUrEkEEVqiHqyLd8/FPIyRTdmOaVTzQU/IuREKoFTI21lPvVEvgCpo33FcdzVIwlE8E/a1QmXS5MfKe/wCdfOq/6xfqK+k/2s1UW+mE/er5rT76/UV0I+fxf8QdJ95vqa+sP2KZs6ZrUXpID/Kvk9/vv9TX0r+xVd7dY1m1yMsitj/P0powifVUn3z9ahfpVqRfnbioZFrRSOiLKu3nmnbQRTttANEka3K0iVlXsfNbMxFZl0Mk1x1UdFGWph3AwaqpyetaF1HkHmqCjapJrksepB3RVuFALfyrGnXExPatec4Y9az7lM81hJanVHYpzqTHwSAPSqE6fPkdMVqTAGPB5qqUDKVyeOfSglme6hojxyKfaNyQM5HNRb1VZFPr9aEciRSq54q4sho6nR91yoVh7g1HdwhZWK8NnHFQ+Erny7krIflzx9ak1q4SHVJVlG1GIIbrzVVY6XMU2nYI3C8jIJ6ipY2aQgbee/NVZGEXynqeQ1OjkkRWwQMn0rnLC65cLycnJqjePuyBn8KnnfLnABP8qo3SMqZJxn3qTRFa52NG4JI6Ae1VGxuGeu3GfWrcgHlhRgeuRVSRxtPGP60XBlK4/i7YH51zl5LG90IXU7iRhugFb07FicgkCuUaZbm7meMkJnC5Fa0Y3dzmrVOVWJLi3eOZtvG4YJB4qa2mO4qcHouKt2oM0O3/AJap09xWZLutpy+Tgt6V0smnO5LekYMbEDPAxVNziQOCcZA69as3g85DJGju0Y3PtHb1qrJgwLgnHUd6xkjqjLU6jSlAlTnknk5zXVxNuwsbgqBXJ6CpbDAZwuPeuksPmYDbz9a5HuenTfumjGAigOcnrxWhBMoH+1jjiq25E27UBepVVjcIcYBrSApal2B2cjdwT2q35R9arKQkyAcmrqgjk10ROSb7EUjYAHNNaMAA96WQhvqKaZMsqg0OQII2Kv7VbHzAGmpEBzU3AU0RM5SuCDfUkYCmolbaPrSBiDzVGbTZKzc5NVnBZuKe7H8KkjXKg461Q17uo1FwtOCE1Ls9qmWP2q4ohzIUTHUU9kGOlS7eaUrxWnLczcio/t2qMetSuOelRNwarlsaoHPy0tscyL9ajfntU9khaZPrQhysos8M/a0mG7TIgeev86+ck++v1Fe8ftX3O7xDYwYPypnr7f8A168HT76/WuiJ8ziv4gr/AH2+pr3H9kO/Fr8R5ICcCeHA98f/AK68Of8A1jfWu9+BWqf2T8TtInLbVd9h/H/9VNGEdz9Cp+HNV5DU9yQyI69CM1TY5NNLW5tTWgpOajxT8cUx60ZsiGUVnz9a0JOlULjqa5pxOiluUJxycVnTrtBrVI3A1RuU4NckonfSlbQxJ15PpntVSQZ4POa1ZI9xYEVQkj2k9K55RO+LuZ0x2Hp9aqT43DB25rQuEGT1rOuCqk9eenNZlNGfJkb89fao4jlOOoq2yggleveqgGzdz3qkZssaXO0V7lievetPUCtxcSJKxycEVijllYHBHWpt5l1Jd27BUcg4rZaqzM5R6o21TfaiNx8y/d96iYYhJTGAeRUeoXflxp5eWaMjj2qdHBiEifdfmsZRsyLjHwF5wPYVnyuGlIJOzGBxV6bOCzd/eqLgLAzN1zWLLiynMxXPGSPUVTunHl8dh0zU8xULvV25HIrPuDhCWIY9QKlauxUnZXKevTQWXhbbskbVb6YRpx9xfQVy+nlAYoV5kLCPBP8AFnGK7HwJPqWseNtMEWm2l/ZITIqSMGwemcH7v1rT/aE8FQeHV07xPpKCz8+8iW7gXBjjYn7w/EfjXrUsNaKZ49bEJz5TlAsljq8lpMpW5t32yow5Hel1q2JcmPp98Y6Yrofi1bpL4z0rV7MpJ/alssUrKNoMqDGSO2QRVXUrU21lp6smJJY28xS2cEHFRONi6MznbV5V0e4ltrgpNI4ieMcZT1qtMAkSgAY6Vf8AD9naXFzq1rezeVstmltiX2guO2aZq+nNaWlntjYtLGjPh92GNZTWh3Rnqa2jAou7kMwHSt6zX9+pyee/pWJpUbRTvDKpDxr0JrcsJN245yBXHJanr0n7puwojIzAk47mpoJCSMDPpUFmwAwefWp4pgmdvNUhSZPFu80Nn5h2rQRySc1nSqGAZMh/Wrdu5dB2PTNaRZhNX1EcHeeTj0psRxLyOKk2kHnBNTQxc7mGKtK4nJJE4JI9qQjjFPXkjHSnHgk1UTC43otNcgj0pXcAVHnIz2qhpdRpb5sVYjY8VXUAtmrEfFK4TJi2PrViIgrVd8Ee9OgbHWqTsYSV0WQuWAqZoxszVcPgipTJlfet4sxaZSmIBNVmJ3elWJMliaibr9apu50x0BE3D3q9p0f+kL7VVi6cVf08hC8hPyqpJoitTOtK0WfJH7TF59o+IDRg5ESYxXkqffX611/xb1D+0vH+qTBsqJNo/CuQXmRfqK6D5uu71GD/AH2+tXNEu2sNZsbpWKmKZXyPTPNU3++31NIelBktD9NfDN6uq+FdOu1IPmQqT9cVZdcGvNf2ZdfGufDW2iZw0tt+7b/P1FemS8E1S3sbwetiIGlODTCDmnYNaSjZG9iGbis65GavT9apuu6uWTN6empU7YqrcdT6VekTaOaoT/xVzzOym7sz5OHx/Wqkyhjx1q1MOckVVZuetc7O6JnXK84596yL2J92QeK3Jh5jnPFUb5PmX346Vi0dEWZR+VM+gqhId6bh+ea03TDMDnFZ7KFkMZBwTQiJKxCx6cnrU1sVFzlzgetVZm8uVQQRzSSTLkhevTrVpkF5JGfUHbI2HitnTfKkt5YkcMgPBHY1g2D+XdLlgwI5BrZ0zbby3CBQVf5lrXl5kYS3CcMspWY4XsB3qhcuVEy7v3ZHympvEt9/Z8sW5QyNgHIxjPvXP3Wpz3MhjtYFKZxvNc0qbvYcWPuLlAQC2BkLycc1g3N+8t7d2ULBUxsdwM4+hroMQNp2pafeuyhoxLHIFBxKvI98VyN2iQ3kVxGgCzKC20cZ7mrhS5XdkVG2jd+Ek+t6X4wFp4bt4JfLBe7ln4VIepyx6V6D8bfGPh3xZ8MdX0/TL+Oe6LAR7RuBkRgeD6cda830W61DSLq7vtHu1glu7c206socMp74Nc9p1hHp1ulqm07O4AGfevRVZKJ5MqKc+ZnV+KLuHVtR8IXOnxm6nktI5LizhQjbIgAI47mruryXd/PazS6Bd6e8UTGRWjIUgtkHmuSLFZPMt5JIpF6PGxVl/EVsza1qGpPBJqF7POYoxCFLEAqO59TWLaZrFOLMrU4V+3ZKjaQMhhU1y2mTeGrlptRuU1YOPKhEZ2HB4GaNTUeYXH3SKybh90kDbMkMOTzWV7HbDVqx1trOwufMkA3ui5HXt71uQgxklTnd2Fc/CxuZftBXB4ChR1/CugtyZUUAEMo7Vyy3PapaI0otwVURssw5q1aRMvDHJ61RtRJ82Dkj1q/bynYN2dwpIci3I2081ctlEcaBvrWdhnYYyc1fUFjx1X1rRI55kkih5Btp0rmNRzUQOJj9KbISzDHIFXclK5ahkJ781OQduTVOz5Y9MCr0p+T2ppmUtylcEhhj9KcCQoFBweT1qRQMUXNL6BGM8VKRjFJHwTxTn6VUdTJvUM0sbfMKj3YNLEQWzVCaLJbFOWTIqORhjj0qOAksfatERy3RNIVGSRUK/MP/AK1EhJIpR8q5NUUlZCqfzpNbvl0zwpqV45C7YmwT9KaD83WuF/aE1kaR8PWtlfbJc/LgVVN3Zz4l2ifIeqXJvNTurhiSZZGbP1NVk++v1FJ70qffX6iuk+bbu7iyffb60lD/AH2+ppKBH0X+x74oFh4kutFnkCx3Q3ICe/8A+v8AnX15cph/rX5q+B9bk8PeK9O1KJtvkyruP+znmv0h0fUItY0S0v4GDJLGGyPpT8zSL2Y/bS7RTsikJ5puTZrdleeMYqmU54q/KeKqH71ZtG8G7FO6X5ayZzya2rvleKxLlSCfrXLM7sO7lGYFjyeKoXB2t3rRkHJ9KoTrkj2rnkehBlRs5zTH2Y3Sx716YqxKuKjcBoyO4rM1TMG54nCodsTNjLfw1U1q3ksrsRsVcYDK685FaVwqlDlFPOenWsO7Q+exwTkUimrlPUJH84OhzuHPFVVUO3AOevFTy5ZFyPu8YqGAlZG5xxVJmTLUM4kuozjbldrY45rds5S1wFKnCMM4PWuRaQxzhmGVVs9a6bRJ4xJ5jA4bk1vBmUhPEsiahfqHDCKNhuwKggUCBhCoVBzgDBptq/2jU7hRgqZOM1NppZLy6QAfITnFVymbMVm8u9uJN2/d0HUViaim24VFyFboOmK6PAa5JXlWyR7Vj6vH+9hYY3KSOazkir3KNhMDPJHxlhio7kbZdrj5vXFVZmaCVJO+7BqxqeJbdZVPJ700clSOog9QckVNHIpjDDPDVmQSkphnJ9AO9XFfMQGAPamYlyaUSIUfGAOKxHkLMiHG9WrQDSSEtENyhcEd6x5ZM3UDKchumaiWx1UXqdzpbbVh5+6M8dK2LSQiVztbD+9Y2lOOUPZetbMDeWo5PXmudo9qm9DUgl2ZK4weKngm8uYqxySMgVnxoepJCt0FXIkw4xyTUmjSNqJgiqw5JqfeQNxX61mWrF4/n+8p6U6UuRksSvbFaXOdxuy4AXO7NSKuVwBgVUtVkwFY5GKuJuxgHOKaJloS2ymNhnv3qzOyhajVMAN3pswyKq5luyEyr0NOST5agYDPFPK4X0qbmjSLSSAmpSQVqlETu61ZT7vJrSDM5RIZySRinxHA/GnOABUcfOa0ZW6LAbIIzT4Opqv0qWFsE1SZEloS9X5obpTWbBzTVbmncixYtIvMnVcDrXzd+1Lr4u9ft9LhfKQDLD3r6Ta7j07Sru/mIVIkJya+FPHOsPrvim/vmYsryELn0Fb0keVj6tlYwaVPvr9aSlT76/Wtjxwk++31pKV/vt9abQAtfaH7JXjE6x4Ul0S7k3XFmcLk8la+LxXd/BnxfJ4N8c2d4r4t5GEcufQ00VHsfoO6lWIPagUyC7h1CwgvbZg0UqhgRSqwq3sbrVDJRUBFWJeelQEGptdGsdipcrleKyrhea25FyKz7iMfhXJUiddGdjGmTAPpVKRRyfStaVBz0rPmHJHaueZ6EJXM+X5jVZiVY9NtWZQVfiqlySvU8GsGdESlOv3uMCsTUMKSVIJ9D2rW1CQhBtODWNeZKbvUYNTc0Mxjljzwaps2GOCPlbBq0yFVTHY881SvAR5hXGc5qjKQ+cA7mzn1q9pFyqERHJ/Gsyd/lB/hI5ot22ujfKGParizJmpas1vq6GNuN2Tnoa39PgK3d0z5y4Lg9PwrnFi85C0ZxKDkEVr2+qO+EcY2rg845roT0M2ZMZEcccpB/wBYVJ9qy9XJMrMR+73cGtbIWzkib5mDZHFZOpgiONW6EE4qZIm5g3oZo5Mc5wRUVvOZbPBI/dnkUtxJtMYJ6gqTWcJTb3rJkBZF3cVJnNXHwSIHfB5HarguNoVQAPr6Viu5MjMMHParNtJl13dB6mmjna1Lc85DMI3dAeRtOMVn3DbXgQndtOQTSCYNM+OcZxmmXh2PbvgZDcipexvR3O9sJmVFKfxgA+1b0bbZF7nHX0rmtLdmRQvHQmuhGWAYnnpkCudnsU2attvkAG7nPFWo5TEDv+92JrOsmKS/ewAQelXrk73BBwOtTY6L3LlgfMLStkHpir424AzkEVm25IhUAdanMhwOcYpmLV2WoJgHKCpweQB3rOhYBs9Qe9XUYEqQfwqiJRsaIY7Que1NdhsxnmmqQU/2hVdm+fnOabMkgOQu6pW+dajfAT61Iv3aSLHR4HJpwkx6YpgIA5OKizuJrRAlckeXcMZpYDgVXkOwgVKjce1VdjaLCksacp5warwyDfip155qrmch7cCmxZcgDqT6VIRlc1JbNHbxyXc5CxRKWJJqo6mcpJRuebftGeKRofg9NKt5MXV3wQDyBXyPXdfGPxS/ijxjdTKxNvCxjjGeK4Wu2Csj5rFVOefoJTk++v1ptOT76/WqOYH++31ptOf77fWm0ALSk/pSUUAfY/7LPj8axoB0HUJc3VqMJuPJHavcnYo5FfnP4F8S3PhPxJa6naswCMA6g/eWvvnwr4htvFHh211OzcNvQbgD0NaRnbc7KTUlc3/N45ppcE9ao+dnilLEd6q6kjo9mWXYdKp3IJp24mhmyvNc842KjHlM2ZSDk1mXQO7npWxMMg1kXI+cLXHNandTdytNGCmRWTeHjFbj8RkGsS8xlvSuaaOumzKvF/d5OAKypz5i7RzWtcP+4c5+nGayLdwVkbrj1qEbdDLmcwXQH8JGTVWcgynoQelW7hNzYIz3rNk3JcHgge9MykVnJAIzwDyM0qOrYRiQU5FJPh95GACPSqoOZ4WPUjBqoszZvW0+wxsuVx96nSSD7VcAHAb5sg1UtZgB8xx2NJOcsJFPOMHjtWyZk0WfPDRsoI56MKzdUkM0EKEEvH1we1Wom2W0uDwozx2rMuW3/vAxz09jVXuQYOoSjeDyMPnkVmanKFurZgTlwenFWfELGNgFPDEEeua53UtQjgvAXzI6R4RBzj60JXIm7I0EcMhk81V5wB3q5a3SxLudhjoCa5WC6uZ3wkcSnr06VdS9uYABLGhU++KrlaObc23cSXW/OQy9gMVWvZAZEUEN8wAFU0u3MTnCk9eB0pt1MPJhZARIGB69Klo3p6M9E0zclz5TAqygE/lXSI4Kg5xXMQ3Sz6p5uVzLAhwOmcVvWj/uzuAx2rle56sHobVvIuCc/MMVeZ9xUE8dqxLecZxjPpk1sJzsYdhwKk3TL0buPm4KjtinKfMOSOM1SjkLBtw6H1qwZiU4wPc0xlrOzGw9e1SKduGPUVQ80l0xjAq7GoYEkGhCaNG2k3vkjg+tJcArJnt9KpRyNE4HUVbZy5Gc470zPlsxjybTgnipI5SF+tVpv9YAMYqXIC8H8qCnFD2kOzApInOcHrVXzNjVNC25wRVXBqxJJyCeOKfEfk7Uy4OEyOtEX3BnvTvYlvQlh+97VaRwDiqgG1S3pQrHqTVJmclc0kO/5V5JOK86/aB8YJ4d8L/2XZyAXt0MHB5Arvbq+t9E0i41S9YKkSEjPevjD4heJ5/FfiW5v5mPllisYPZc11UY31PKx1f2cbLc5rJLFm5JOTmkPWlP/wCqm11HghTk++v1ptOT76/WgAf77fWm05/vt9abQAUtJS0ALjivbf2c/iO3hzWF0fUpSbC5OELH7p9K8RpysUZXQlWU5BHagunNwdz9IpArKs0Lbo3GQRTC5xXi37OvxNTW9PTQtYlAvIgFRmP3xXuE9v5Z9u1Wtj1YTTSGx8rmmSHjFOi4JFNmGOamexXUqTvxiqbxhmB6VJdSc+9RFgQOa4pI6oqyIb9dsZIrnLo569K6S5O5SD0xWBqKjIAzXNUR1UWYUpDF0JOSMjtVG2jOyQA4JNXZ/vZPBqCDiYgHGazSOh7FDYSxz9Ky7wfvcDsa6OdFAOB+VYl3ECxGeTzTsZMybtGwSoOaz5SXjI2jfHyCa2JfkZQ2cd/ese8Ux3DeWOoyM+lNGUkW7OYTRHIySOw708O/2Yn5vlOGGO1UNPnC7kGCw7Yq5K5O5l4GzBGetaGYQT/u2XcQMc+4qmzBo3KFSMZ4obchDrypHOOaqeYoLFGyGGCMVSZLMPxHKA0LuAFRS2Sa4SJ2uriSVj88h4x2Fdb4onAspCSBjK461ydmCsKthsD2/rW9NaHFWd3Y1rb93GQoBboT0qW4XzDGD1A55qvbYUK2QCeRluauuu6F2YgetNiiisAVjxg8+1WLZRLfWMJwFklCnPpmmJCzxF8fKo+lRQTOPLYnaY5AwI6jBrNm0NzubuFdM8TyWaHdHGMKfaumtZ1aLg44yAeK4iG8a61vz5XLOVABNdJYSlT5RAGeV5rlktT04PQ2oZQ3lsuCT1BFbJl+QIVORzuFczHlgwUnA5GDW9ZuHiynXHOTUGyZpwuDtBPPvU8jMICNwIrODYKnPGKlZmlwAeKY7l2JtsaZA+tWo5x5iryAapRsdo9BxUrqd6lelKxSdzSlwuKlSXcnBFZ0lwWAXHNMSbacc/hTCxdDESfNSTTBXAOcUikMQSeabcR4II6UD0HO28gircPyIM9apx474xVxcHnPSkmTJkx2kDIpM4bHHFRhs8ZprN855xVXuZEzNuYDtVm3i8yQFuI15JNUo1ZpFVOWNcR8ZPH0XhnRm06wkVr+YbTj+GtqcXJ2Mq1RUouTOE/aE8f/ANozroGly/6LCf3pU/ePpXh3Tj1qSWR5pXmlctIx3EnqTURNehGPKrHy1eq6s+ZhSUppKoxCnJ99frTacn31+tAA/wB9vrTac/32+tJQAlLRRQAUCigUwLukajdaRqMF9YymOeFgysK+3/g18SLLxzoEcNxIqanEoV0J5yK+FK1/C/iC/wDDWrRX+myskiEbh2Yehpp2NqVTldnsfoc48pyGqOVgwNcN8L/iHYeOdGjzIsd+gw6Hg5rsmYoSrdamclY9WHvamfeMR0waqoSx54qa/Pykiq1sGJPpXHfU7Y7FmZcwHaK5y/3BskCunU8bR096wNSUCU9MZrKpE1ovU5+VMkHAyTjFVAv+lHIwV55rUlAB7VUkiXeHAwaxRu2JLhTzjnms3UoCu2RRlW7+laZPm84BotUjniaGbvnBNXa5BzFwjOhx27ViamhDpIoIC9a6O4iNtcOjDjPT2rLv4Qyso5HapasQ9Tl5S8c3nRk5z+YrRgn822O3nnB5qrKm0urfhzVW3cwXGw/cY8+1WjJmnPkW/G47fyrHWbbc7W6vzitqGUAsp5XGCK5/UD5V9bDd99+lNEs5jxpMVxb9jJn8KyoItyKOnPXOOKs+JHW58S3ATmKI7RmhQFCqFCt1rqWiPOk+aTZPbhnuiqfMUXPy84FTQs04Gcne2cY6CoraR4xOY+sqhPwp1u3lu+cYVcCpZaLt4VSERx8Fj2NZ338p1AzmrbZKBnYbsZ6dKqMu3OMkk9x3qTSJqaXP/qyRhoyFPoa6pZvLCyc7gQfwrkPLjtDHGp+dhljmuhtpmuLFVJywGDWM4ndSnodNZuFuWJHyuMjNa1nIcYUAZ4zXNWcnmW6nnIAGM1tW7bR9/HesrG6ZsiQiEKW61ahIyoBx+NZLEqE6lW/SrtsV2sB1FFirmqSu3I59aUSZTjoe9UmcoMcYPelJ2qADz1pWKTLO8rIGYDFTO6iUEY5qrHKZCVcYzTidsgUcnGeaRdzQDKdpUkVbYhkHfNZ9kxJORx2zVm5lIjwMntQK+pEzHzcLwBVtGwAP61nk/dA/nTjMQwyegpAy+ZCpxzmmxsWlCgZYmoo283AXkms/xb4ksvB+nPc3Lqbvb8idxWkYuTsjKU1FXY/x74rs/BehvLI4a+dcIvUivkrXtWudb1Oa+vXLySNnB7D0q74u8R33ijVJLu9kYrk7VPRRWHnA46V6NKnyI+axmLdaVlsIzc+wptBPaitThEooooAKcn31+tNpyffX60AEn32+tNp0n32+tJQAlL2oooAKKKKYC5o7UlKKANbw1r994c1SK+06VkdSMgHhh6V9ffDH4naf4y06OG5kWHUFABDHGTXxZVvStRu9JvEurGVopUOQR3+tKUbnTh8Q6bs9j77vEYEq3Tt70yE4Xj0ryL4UfGC01qCPTdfcR3IGA5NetnGPMjYSQsMq68iuWUbM9unNVFdEgY7ie1ZupqhjyTyasSSDbwelY91cs77ST68HrUS1OmEXuUrobRxn86ifGwYxS3kg3AZ9+aarZZM8CsbGrK5TDJk8k5qFspIdvfpVy4iLsGB4HaqdwSrrj15xQtBXM/UAXfcfveuay5grJzww6Gtq+QEZBGfQ1iTEN8gGHHNJohmJqUWCTx+ArInUFsD17iui1BSUbAH4VhXa4jLYIx1yKaM2QQyliUbGRxms7XLlUkikYkeUCxyR2pxmxNGFJ61zXiu8M94ltGcqfvGrjG7MKs+WJkAvI73Lgl5GLdPWr9u2H9WxyM1AQgmC/wAMS54BFTWJyjkjBbnk10HCnct9AVGN7cgHnAplqqxoHYYye+RmiVgI8AESOMDPYUyd8RqOgUYHNJmqLZYsWkwdhOOPSruh2qyO99cn/R4yQue5qHSbFrqP5uR6Gtm52Wunw2UYUc7mC+tQWtTH1DEtw0sfAB4461bspTGm7GC3c0SQlk2g5Heq6ElWQg7o+MeoqHqdEHY6KwnwGQHHQ9a37GUyK0bZDY4JrkLCYAJh/nJwRXRxSCPYzDk8ZrNo6Ezdj4UPjOFxinQTmMszcDPI9qqCQiPcGyKkgfdLwMhhSsUma8rA4Ze445phlJfB6r2BqKGQsuCQCPWmFvmaTHOOallqRfjk3EEDGOaltpSzyNwMcVRjmCgPgEEdhU9k6srZ6E+tTYrmNezk+VR2z2qxcspTC4J9DWTbzhZG5OB04qbztz5H86qwr6j4WJfLED8abcK0kiLFhmJ5FIsb3Evynao6k9BXJeNfHdh4at5ILKQTXxBG4c4pxg5OyJqVo01zSZ0fijxXYeD9NaSWRHvSPlXPQ180+K/Ed94n1N7m8kYrn5UzwBVTWtXvNau2uL2UuSeAT0rPOBwB+dehSoqCPncXjHWdlsIeOOQPekJpSabWxwBRRRSASiiigApyffX602nJ99frQAsn32+tNp0n32+tNpgFFFFABRRRQAUtJRTAWlpKKAHI7RurxMUZeQQcGvY/hj8Y7vQylnrJM9r0DHn868aoNJxTNaNaVJ3ifd+iatp3iCzW50m4RywyUzyKqaihif5l2tXx34U8W6r4Zu1m0+4cIDzGW4Ne++Ffi/pniC3S21gG3uem+uapTtqj3MLjYVNHozs5SJBkZ4PTrUcjAMF6A88GlWINF59pKLiA8hkbNQeZiUbxjt0rm6nfcszS+XGGyarXBDssigjjmo5JtrBSRgnFDnjB4A/Wm0K5Vcl42B5xWVdx4YMBzjrWjI3zEAcVTuxlOvP1qWiGzImbqOcH9KxrwK0MqjG7P0rSu32hAQQM9QM81j7w096HJwoJGee1JEM5G8vfLuCu7GFPOelc0hJmM0mGYk9ammmeQuzDdvc/N1qPb8m87c52jgiuqEbI86tPmdhVJMb7iTk5POKuW+0RKWO1B1B5zWezD5vmwoPJzVqHMzbVU7B/FjirZnElVjLIZBj0GMgYpxTzZFVQSikbj71OE8qDoSx6UWSyXVzHZgEKAZJDjNZmyNe1kCJ5MC4x39KsKpdvNY7ux9aY1i1oFbeuGGdvepYiVRtvp3NZtm0VpoSSIAm7A59azZiYbsSIMAjBwK0zgqWAx2+tUbhchh83HPWgqJPalHuYm27lL8811F9GkUhjXaAcEbTux+NcVbNt6k7WPcdK3YrkKiLlsjvUtGyZrwzZXbu2kdfetC0YH+IADnNc5v8AkYliSB61etrgJbqwJOfSpsWdDHJlWbcPloEm4k54PXmsy3mZllwTgjjFOhuBxGD8x6g0mtCkaccoQFD26GrSZSLcMc89axopCXdd3I4GTita0zLbkyfKqjlieKixaZLFMDkDk5rSDwW1t9ovpVgiAzyeTXE63410zQFcRbJ7kjj0BryPxN4x1PXpW82ZkiP8INb06LkcmJxkKPqd/wDED4oeYH0/Qhtj6FxzmvILieW5laady0hPJNRY/Oiu2FNQWh4VfETrO8hS3GD0zTTR2orQ5wP1pKCaKQBSUtJSAWkopaAEpyffX60lLH99frQAsn32+tNpz/fb60lUAlFFLQAUlL3ooASloooAKKKBTAKKKDSAXNAJU5UkH1FJRQB2HhL4gaz4clXyZ2lgHVHOa9i8O/EzRPEQji1AfY7n16Zr5uoGQcg4IrKVGMjso46pT0eqPsQ2y3CLLZypcRYzlG5qO7TCqfm44wa+YvD3jPWtCmV7S7kKD+BjmvUNE+MlvdoItdtgDjHmKOa55UZI9OnjqdTrY9CwGU81n378noMUljr2jalAGsL6MFudrtTL6OUQl0AcZ6qM1lJWOlSvsYWqfNbyumdykNgVx+qX32WwuZif3ko2qM9Sfauyu5AIpkbOdhzxXlGqXX2q4RFY7Y+ABzk06cbsirPlRVgQeUitk/X1pHYAAYwoPr1p2DkFzgjjpioJTvA+8Vzwc8V1JHmt3ZEyebJBG3AeTBOe1dldQWlsqxr/AKlVHAXG4/WuTiTzLuEByGDDPHGK39TuvOm2Jny1A6etKSHFalK5cCNs/Kc8c0aLK0V5KyEfMmMkdqivWy6gFiSPrSRDEi4DY6dMVD2N1ubwkZ41ZmZnzjJOABVu2GFbOAB+OaoWwHCnnHbNaKZAO4gDtxWTN0OZVb2xTZFLA/3enWlCFucYH1oyBlSAPwpIZlyRFBInAB5HFXUfdDG4JzjHWo7lMjccAe5pto2UMZI54602iosvxSkrl8YPtmrtrIRAUOAAeetZkMcu0jaQQfSrAmgt4N9zcIueoDc1NjS66mrbXPlKAvdsetWlifzN/CBTyTxXE3HjG0swUt08xlPDEZrm9X8W6lqLHMzInYKcVcaUpGFTGU6fW56Zf+JdL0kFnl8+cHkA8ZrhvEnj7UNU3RW58qDsAMVxkjtI252LE+tJXRChGO55lbMJ1NI6IfLJJM5aV2ZvUmmdKKStjhbb1YZooopiCkpaSgAooopAFFFFABRRRQAU5Pvr9abTk++v1FACyffb602nSf6xvqabVCDqaKKKQwooopgFFFFABRS0lAgoopaBgKO1FFMQUUUUgDPaijrRQA+GeWE5ikZT7Gug0zxprVgoSO7dk/utXOAkdKSpcIy3NYVpw+FnoX/CyJ5o2W5tlYlNpI6muat9RtzkuCrEk8VhCioVGMdjZ4ypL4jphNbScrMB9c0OivggoSBxzmuazShmHQmnyCWI7o6e2gk37tvFXArgEbMEe/NcglzMn3ZGX6Gpl1K7XOJ5OevPWk4M0jiYm9IpaTODgegqaJXDZ2HOeOa5wandAg+YeKeur3ajCykc5qHTZpHFQR39rAwCEoSxHYVdgicsQ6dK87PiLUDj98aifXdQY/8AHww+lR7GRq8bTR6l9mO0ncqgDOCaqXE1tBnz7iNR7HOa8wk1K8k+9cSH8arvLI5y7sT65pqg+pDx8eiPQdQ1rS4sosjOR1wMCsabxRGn/HtbqD6muUorRUUYyx03tobV74ivrlj+8KAjopxWVLcSykmR2OeetRUVaglsc86857sKB1ooqjIKXocGkooAKOtFFABRRRQAUlLRQAlLRSUAFFLiigBKKWkoAKcn31+optOj++v1FAErwfO3zd/Sk8j/AGv0ooqQDyP9r9KPI/2v0oooAPI/2v0o8j/a/SiigA8j/a/SjyP9r9KKKADyP9r9KPI/2v0oooAPI/2v0o8j/a/SiigA8j/a/SjyP9r9KKKADyP9r9KPI/2v0oooAPI/2v0o8j/a/SiigA8j/a/SjyP9r9KKKADyP9r9KPI/2v0oooAPI/2v0o8j/a/SiigA8j/a/SjyP9r9KKKADyP9r9KPI/2v0oooAPI/2v0o8j/a/SiigA8j/a/SjyP9r9KKKADyP9r9KPI/2v0oooAPI/2v0o8j/a/SiigA8j/a/SjyP9r9KKKADyP9r9KPI/2v0oooAPI/2v0o8j/a/SiigA8j/a/SjyP9r9KKKADyP9r9KPI/2v0oooAPI/2v0o8j/a/SiigA8j/a/SjyP9r9KKKADyP9r9KPI/2v0oooAPI/2v0pUg+dfm7+lFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2097=[""].join("\n");
var outline_f2_3_2097=null;
var title_f2_3_2098="Abnormally short frenulum";
var content_f2_3_2098=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abnormally short frenulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abnormally short frenulum, inserting at or near the tip of the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2098=[""].join("\n");
var outline_f2_3_2098=null;
var title_f2_3_2099="Patient information: Prostate cancer (The Basics)";
var content_f2_3_2099=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15415\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/32/37382\">",
"         Prostate gland",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/30/12768\">",
"          Rectal exam",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/59/23474\">",
"         Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/15/3315\">",
"         Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/55/38770\">",
"         Patient information: Prostate cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/39/40565\">",
"         Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/41/42643\">",
"         Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Prostate cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/prostate-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H457221521\">",
"      <span class=\"h1\">",
"       What is prostate cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Prostate cancer happens when normal cells in the prostate gland change into abnormal cells and grow out of control. The prostate gland makes fluid that is part of semen. This gland sits below the bladder and in front of the rectum, and forms a ring around the urethra, the tube that carries urine out of the body (",
"      <a class=\"graphic graphic_figure graphicRef65675 \" href=\"UTD.htm?36/32/37382\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Prostate cancer occurs most often in men older than 50. Although prostate cancer is very common, most men do not die from it. This is because prostate cancer usually grows very slowly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H457221528\">",
"      <span class=\"h1\">",
"       What are the symptoms of prostate cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Prostate cancer often causes no symptoms at first. But if symptoms do occur, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Needing to urinate more often than usual",
"       </li>",
"       <li>",
"        A urine stream that is slower than usual",
"       </li>",
"       <li>",
"        Trouble having an erection",
"       </li>",
"       <li>",
"        Blood in the urine or semen",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms can also be caused by conditions that are not prostate cancer. But if you have these symptoms, you should let your doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H457221535\">",
"      <span class=\"h1\">",
"       Is there a test for prostate cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors use a blood test called a PSA test and an exam called a rectal exam to check for prostate cancer. In a rectal exam, your doctor or nurse puts a finger in your anus and up into your rectum. He or she presses on the rectum wall to feel for abnormal areas on the prostate (",
"      <a class=\"graphic graphic_figure graphicRef80412 \" href=\"UTD.htm?12/30/12768\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      If your doctor or nurse suspects you have prostate cancer, he or she will follow up with one or more tests. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Biopsy &mdash; A doctor will take a small sample of tissue from the prostate. Then another doctor will look at the sample under a microscope to see if it has cancer.",
"       </li>",
"       <li>",
"        Ultrasound, MRI scan, or other imaging tests &mdash; These tests create images of the inside of the body and can show abnormal growths.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H457221542\">",
"      <span class=\"h1\">",
"       What is cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out how far a cancer has spread.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H457221549\">",
"      <span class=\"h1\">",
"       How is prostate cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Men with prostate cancer often have a choice of treatment. Treatments options might include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         &ldquo;Watch and wait,&rdquo; called active surveillance",
"        </strong>",
"        &mdash; Men who choose this option do not have treatment right away. But they do have routine tests to check whether the cancer starts to grow more quickly. If so, they can start active treatment then. &nbsp;",
"       </li>",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &mdash; Prostate cancer can sometimes be treated with surgery to remove the prostate gland.",
"       </li>",
"       <li>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        &mdash; Radiation kills cancer cells. Radiation can be given from a machine that moves around your body. Or a doctor might put a source of radiation directly into the prostate gland.",
"       </li>",
"       <li>",
"        <strong>",
"         Hormone therapy",
"        </strong>",
"        &mdash; Male hormones in the body make prostate cancer grow. Hormone therapy reduces the levels of these hormones, which can shrink the cancer. For hormone therapy, men might take medicines. Or they might have surgery to remove the testicles. (Male hormones are made in the testicles.) This treatment is usually only for men with advanced cancer. But some men with early stage cancer get it along with radiation or surgery. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H457221556\">",
"      <span class=\"h1\">",
"       How do I choose which treatment to have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You and your doctor will have to work together to choose the right treatment for you. The right treatment will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The stage of your cancer",
"       </li>",
"       <li>",
"        Your age",
"       </li>",
"       <li>",
"        Whether you have other health problems",
"       </li>",
"       <li>",
"        How you feel about the treatment options",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H457221563\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, some men keep getting checked to see if the cancer comes back or starts growing more quickly. Other men choose not to be checked. Follow-up tests can include PSA tests, exams, biopsies, or imaging tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H457221570\">",
"      <span class=\"h1\">",
"       What happens if the cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the cancer comes back, you might have more radiation therapy, surgery, or hormone therapy. You might also have chemotherapy. Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H457221577\">",
"      <span class=\"h1\">",
"       Can prostate cancer be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Men who are at high risk of getting prostate cancer can sometimes take a medicine to help prevent the disease. If you have a family history of prostate cancer, talk to your doctor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H457221584\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/15/3315?source=see_link\">",
"       Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=see_link\">",
"       Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42643?source=see_link\">",
"       Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/55/38770?source=see_link\">",
"       Patient information: Prostate cancer screening (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?2/3/2099?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15415 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2099=[""].join("\n");
var outline_f2_3_2099=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457221521\">",
"      What is prostate cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457221528\">",
"      What are the symptoms of prostate cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457221535\">",
"      Is there a test for prostate cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457221542\">",
"      What is cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457221549\">",
"      How is prostate cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457221556\">",
"      How do I choose which treatment to have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457221563\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457221570\">",
"      What happens if the cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457221577\">",
"      Can prostate cancer be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457221584\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15415\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/32/37382\">",
"      Prostate gland",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/30/12768\">",
"       Rectal exam",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/15/3315?source=related_link\">",
"      Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/55/38770?source=related_link\">",
"      Patient information: Prostate cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=related_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42643?source=related_link\">",
"      Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_3_2100="Selenium: Patient drug information";
var content_f2_3_2100=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Selenium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     see \"Selenium: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      SE Aspartate [OTC];",
"     </li>",
"     <li>",
"      Se-100 [OTC];",
"     </li>",
"     <li>",
"      Selenicaps;",
"     </li>",
"     <li>",
"      Selenimin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to selenium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzyl alcohol, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12116 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-41.196.66.12-C4976706EA-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2100=[""].join("\n");
var outline_f2_3_2100=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220384\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013155\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013154\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013159\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013160\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013162\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013157\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013158\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013163\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013164\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=related_link\">",
"      Selenium: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_3_2101="Mammographic image of a density - large cyst";
var content_f2_3_2101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Mammographic image of a density - large cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 562px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A BB (radiopaque marker seen as a hyperdense dot on A and B) was placed on a palpable mass. The mammogram that followed shows a solitary ill defined soft tissue mass underlying the BB and surrounded by a yellow ring. A subsequent ultrasound confirmed the cystic nature of the mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Priscilla J Slanetz, MD, MPH, FACR.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2101=[""].join("\n");
var outline_f2_3_2101=null;
var title_f2_3_2102="Fomepizole: Drug information";
var content_f2_3_2102=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fomepizole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/39/28276?source=see_link\">",
"    see \"Fomepizole: Pediatric drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/14/22755?source=see_link\">",
"    see \"Fomepizole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F173900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Antizol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15125571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Antizol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F173919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F173901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Fomepizole therapy should begin immediately upon suspicion of ethylene glycol or methanol ingestion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ethylene glycol and methanol toxicity:",
"     </b>",
"     I.V.: Loading dose of 15 mg/kg should be administered, followed by doses of 10 mg/kg every 12 hours for 4 doses, then 15 mg/kg every 12 hours thereafter until ethylene glycol levels have been reduced &lt;20 mg/dL and patient is asymptomatic with normal pH.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F173911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/39/28276?source=see_link\">",
"      see \"Fomepizole: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Ethylene glycol and methanol toxicity (unlabeled use):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F173902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific studies have not been conducted in elderly patients.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F173903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The manufacturer provides the following dosage recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dose at the beginning of hemodialysis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If &lt;6 hours since last fomepizole dose: Do not administer dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If &ge;6 hours since last fomepizole dose: Administer next scheduled dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing during hemodialysis:",
"     </b>",
"     Dose every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing at the time hemodialysis is complete",
"     </b>",
"     , based on time between last dose and the end of hemodialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;1 hour: Do not administer dose at the end of hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 hours: Administer",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of next scheduled dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;3 hours: Administer next scheduled dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance dose when off hemodialysis",
"     </b>",
"     : Give next scheduled dose 12 hours from last dose administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternatively, a loading dose of 10-20 mg/kg followed by 1-1.5 mg/kg/hour continuous infusion during hemodialysis has been described in case reports (Jobard, 1996).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F173904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fomepizole is metabolized in the liver. Specific dosage adjustments have not been determined in patients with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F173877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 1 g/mL (1.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antizol&reg;: 1 g/mL (1.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F173863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F173880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The appropriate dose of fomepizole should be drawn from the vial with a syringe and injected into at least 100 mL of sterile 0.9% sodium chloride injection or dextrose 5% injection. All doses should be administered as a slow intravenous infusion (IVPB) over 30 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F173879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of methanol or ethylene glycol poisoning alone or in combination with hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F173915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pediatric administration; treatment of propylene glycol toxicity",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fomepizole may be confused with omeprazole",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F173917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10% (&le;3% unless otherwise noted):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, facial flush, hypotension, shock, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (6%), drowsiness increased (6%), agitation, anxiety, fever, lightheadedness, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Bad/metallic taste (6%), abdominal pain, appetite decreased, diarrhea, heartburn, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, disseminated intravascular coagulation (DIC), eosinophilia, lymphangitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Application site reaction, injection site inflammation, pain during injection, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Backache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Nystagmus, transient blurred vision, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Anuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Abnormal smell, hiccups, pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Multiorgan failure, speech disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Mild allergic reactions (mild rash, eosinophilia)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F173883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fomepizole, other pyrazoles, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F173867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; metabolized in the liver.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; excreted in the urine; dialysis should be considered in addition to fomepizole in the case of renal failure, significant or worsening metabolic acidosis, or ethylene glycol/methanol levels &ge;50 mg/dL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Pediatric administration is not FDA approved; however, safe and efficacious use in this patient population for ethylene glycol and methanol intoxication has been reported (Baum, 2000; Benitez, 2000; Boyer, 2001; Brown, 2001; De Brabander, 2005; Detaille, 2004; Fisher, 1998).  Consider consultation with a clinical toxicologist or poison control center.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Should not be given undiluted or by bolus injection.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F173897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Ethanol decreases the rate of fomepizole elimination by ~50%; conversely, fomepizole decreases the rate of elimination of ethanol by ~40%.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F173873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F173886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F173906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16355483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if fomepizole is excreted in breast milk. The manufacturer recommends that caution be exercised when administering fomepizole to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Antizol Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/mL (1.5 mL): $1849.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fomepizole Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/mL (1.5 mL): $1290.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F173875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fomepizole plasma levels should be monitored; response to fomepizole; monitor plasma/urinary ethylene glycol or methanol levels, urinary oxalate (ethylene glycol), plasma/urinary osmolality, renal/hepatic function, serum electrolytes, arterial blood gases; anion and osmolar gaps, resolution of clinical signs and symptoms of ethylene glycol or methanol intoxication",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F173878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The manufacturer recommends concentrations 100-300 micromole/L (8.2-24.6 mg/L) to achieve enzyme inhibition of alcohol dehydrogenase; according to practice guidelines, serum fomepizole concentrations of &ge;0.8 mg/L provide constant inhibition of alcohol dehydrogenase",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antizol (GB, IE);",
"     </li>",
"     <li>",
"      FomepizoleAP-HP (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F173866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fomepizole competitively inhibits alcohol dehydrogenase, an enzyme which catalyzes the metabolism of ethanol, ethylene glycol, and methanol to their toxic metabolites. Ethylene glycol is metabolized to glycoaldehyde, then oxidized to glycolate, glyoxylate, and oxalate. Glycolate and oxalate are responsible for metabolic acidosis and renal damage. Methanol is metabolized to formaldehyde, then oxidized to formic acid. Formic acid is responsible for metabolic acidosis and visual disturbances.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F173882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of effect: Peak effect: Maximum: 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Readily absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.6-1.02 L/kg; rapidly into total body water",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to 4-carboxypyrazole (80% to 85% of dose), 4-hydroxymethylpyrazole, and their N-glucuronide conjugates; following multiple doses, induces its own metabolism via CYP oxidases after 30-40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Has not been calculated; varies with dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (1% to 3.5% as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barceloux DG, Bond GR, Krenzelok EP, et al, &ldquo;American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Methanol Poisoning,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2002, 40(4):415-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/12216995/pubmed\" id=\"12216995\" target=\"_blank\">",
"        12216995",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barceloux DG, Krenzelok EP, Olson K, et al, \"American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee,\"",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1999, 37(5):537-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/10497633/pubmed\" id=\"10497633\" target=\"_blank\">",
"        10497633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Battistella M, &ldquo;Fomepizole as an Antidote for Ethylene Glycol Poisoning,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(6):1085-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/12022913/pubmed\" id=\"12022913\" target=\"_blank\">",
"        12022913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baum CR, Langman CB, Oker EE, et al, &ldquo;Fomepizole Treatment of Ethylene Glycol Poisoning in an Infant,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 106(6):1489-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/11099610/pubmed\" id=\"11099610\" target=\"_blank\">",
"        11099610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benitez JG, Swanson-Biearman B, and Krenzelok EP, &ldquo;Nystagmus Secondary to Fomepizole Administration in a Pediatric Patient,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2000, 38(7):795-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/11192468/pubmed\" id=\"11192468\" target=\"_blank\">",
"        11192468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borron SW and Baud FJ, &ldquo;Intravenous 4-Methylpyrazole as an Antidote for Diethylene Glycol and Triethylene Glycol Poisoning: A Case Report,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1997, 37(1):26-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW, Mejia M, Woolf A, et al, &ldquo;Severe Ethylene Glycol Ingestion Treated Without Hemodialysis,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 107(1):172-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/11134452/pubmed\" id=\"11134452\" target=\"_blank\">",
"        11134452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brent J, McMartin K, Phillips S, et al, &ldquo;4-Methylpyrazole (Fomepizole) Therapy of Ethylene Glycol Poisoning: Preliminary Results of the Meta Trial,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1997, 35(5):507.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brent J, McMartin K, Phillips S, et al, &ldquo;4-Methylpyrazole (Fomepizole) Therapy of Methanol Poisoning: Preliminary Results of the Meta Trial,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1997, 35(5):507.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brent J, McMartin K, Phillips S, et al, &ldquo;Fomepizole for the Treatment of Methanol Poisoning,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(6):424-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/11172179/pubmed\" id=\"11172179\" target=\"_blank\">",
"        11172179",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown MJ, Shannon MW, Woolf A, et al, &ldquo;Childhood Methanol Ingestion Treated With Fomepizole and Hemodialysis,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(4):e77-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/11581485/pubmed\" id=\"11581485\" target=\"_blank\">",
"        11581485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Brabander N, Wojciechowski M, De Decker K, et al, &ldquo;Fomepizole as a Therapeutic Strategy in Paediatric Methanol Poisoning: A Case Report and Review of the Literature,&rdquo;",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 2005, 164(3):158-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/15578220/pubmed\" id=\"15578220\" target=\"_blank\">",
"        15578220",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Detaille T, Wallemacq P, Clement de Clety S, et al, &ldquo;Fomepizole Alone for Severe Infant Ethylene Glycol Poisoning,&rdquo;",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2004, 5(5):490-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/15329167/pubmed\" id=\"15329167\" target=\"_blank\">",
"        15329167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fisher DM and Diaz JE, &ldquo;Pediatric Methanol Poisoning Treated With Fomepizole (Antizol&reg;),&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1998, 36:512.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hung O, Kaplan J, Hoffman R, et al, &ldquo;Improved Understanding of the Ethanol-Chloral Hydrate Interaction Using 4-MP,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1997, 35(5):507-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobsen D and McMartin KE, &ldquo;4-Methylpyrazole - Present Status,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1996, 34(4):379-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/8699551/pubmed\" id=\"8699551\" target=\"_blank\">",
"        8699551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobsen D and McMartin KE, &ldquo;Antidotes for Methanol and Ethylene Glycol Poisoning,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1997, 35(2):127-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/9120880/pubmed\" id=\"9120880\" target=\"_blank\">",
"        9120880",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobsen D, Ostensen J, Bredesen L, et al, &ldquo;4-Methylpyrazole (4-MP) Is Effectively Removed by Haemodialysis in the Pig Model,&rdquo;",
"      <i>",
"       Hum Exp Toxicol",
"      </i>",
"      , 1996, 15(6):494-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/8793532/pubmed\" id=\"8793532\" target=\"_blank\">",
"        8793532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobsen D, Sebastian CS, Barron SK, et al, &ldquo;Effects of 4-Methylpyrazole, Methanol/Ethylene Glycol Antidote in Healthy Humans,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1990, 8(4):455-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/2212566/pubmed\" id=\"2212566\" target=\"_blank\">",
"        2212566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jobard E, Harry P, Turcant A, et al, &ldquo;4-Methylpyrazole and Hemodialysis in Ethylene Glycol Poisoning,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1996, 34(4):373-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/8699550/pubmed\" id=\"8699550\" target=\"_blank\">",
"        8699550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMartin KE and Heath A, &ldquo;Treatment of Ethylene Glycol Poisoning With Intravenous 4-Methylpyrazole,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1989, 320(2):125.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/3/2102/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8633 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-F17749F6BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2102=[""].join("\n");
var outline_f2_3_2102=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173900\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125571\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173919\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173901\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173911\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173902\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173903\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173904\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173877\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173863\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173880\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173879\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173915\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914140\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173917\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173883\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173867\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299362\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220494\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173897\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173873\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173886\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173906\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16355483\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323159\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173875\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173878\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038622\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173866\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173882\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8633\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8633|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/14/22755?source=related_link\">",
"      Fomepizole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/39/28276?source=related_link\">",
"      Fomepizole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_3_2103="Natural orifice transluminal endoscopic surgery (NOTES)";
var content_f2_3_2103=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natural orifice transluminal endoscopic surgery (NOTES)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/3/2103/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/3/2103/contributors\">",
"     Pankaj J Pasricha, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/3/2103/contributors\">",
"     Homero Rivas, MD, MBA, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/3/2103/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/3/2103/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/3/2103/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/3/2103/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/3/2103/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/3/2103/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural orifice transluminal endoscopic surgery (NOTES) is an emerging field within gastrointestinal surgery and interventional gastroenterology in which the surgeon accesses the peritoneal cavity via a hollow viscus and performs diagnostic and therapeutic procedures. NOTES is evolving rapidly, presenting seemingly limitless possibilities for innovation, technique, and device development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL EVOLUTION AND DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of flexible transluminal endoscopy, a term used before NOTES was coined, was first developed by a multicenter team of investigators (the Apollo Group) in the late 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/1\">",
"     1",
"    </a>",
"    ]. The publication of the initial animal studies generated a wave of enthusiasm and many centers began experiments of their own, using the NOTES approach for a variety of operations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/2\">",
"     2",
"    </a>",
"    ]. These have ranged from diagnostic explorations of the peritoneal cavity to complex organ resections including pancreatectomy, splenectomy, and nephrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial approach was transgastric, but more recently NOTES has been performed through several other orifices, resulting in transcolonic, transvaginal, and",
"    <span class=\"nowrap\">",
"     transurethral/transcystic",
"    </span>",
"    approaches. The approach has also been extended from the peritoneum to other compartments in the body, such as transesophageal approaches to the mediastinum and heart, transgastric intrauterine interventions in pregnant animals, and novel approaches to the vertebral column [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given this flurry of activity and mounting enthusiasm, in 2005 the American Society of Gastrointestinal Endoscopy (ASGE) and the Society of Gastrointestinal Endoscopic Surgeons (SAGES) came together in a consortium (the Natural Orifice Surgery Consortium for Assessment and Research, or NOSCAR (",
"    <a class=\"external\" href=\"file://www.noscar.org/\">",
"     www.noscar.org",
"    </a>",
"    )) to provide consensus and guidelines on how best to bring this procedure to the clinical mainstream. In the last few years, an increasing number of NOTES procedures in humans have been performed. However, technological limitations of the current flexible platforms have been a major challenge, limiting the adoption of this approach (to date) to a few major medical centers. Nevertheless, while it is still too early to predict its ultimate role and value, it is clear that NOTES has dramatically altered our perceptions of how to approach gastrointestinal surgery.",
"   </p>",
"   <p>",
"    A strong argument can be made that NOTES has been instrumental in the resurgence of lesser invasive surgical techniques, such as single-incision laparoscopic surgery, which for some may represent a bridge to NOTES [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. Furthermore, developmental efforts in NOTES have resulted in numerous advanced surgical and endoscopic technologies that are now being applied in conventional laparoscopic and endoscopic techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREMISE AND PROMISE OF NOTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions in the peritoneal cavity were historically performed by laparotomy. In the late 1980s and 1990s, laparoscopic surgery became widely popularized as a less invasive, cosmetically more appealing approach, and it is now commonplace in general surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the same time, there has been a dramatic increase in the complexity of endoluminal gastroenterologic procedures. These approaches differ significantly in the kind of access and viewing perspective they provide and the types of therapeutic maneuvers they enable.",
"   </p>",
"   <p>",
"    Although NOTES procedures have been successfully (and apparently safely) reproduced in animal models, most investigators who have tried to implement NOTES in humans have encountered technical difficulties and sometimes even ethical challenges. These issues appear to be lessened by implementation of hybrid approaches, using a combination of laparoscopic, intraluminal, and transluminal (NOTES) procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. However, the ultimate goal of NOTES is to eliminate the laparoscopic component altogether and perform surgery using access provided by the \"natural orifices\" only (ie, the mouth, vagina, anorectum, or urethra).",
"   </p>",
"   <p>",
"    Enthusiasm for these approaches stems from several reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hypothesis that a \"hole\" in a viscus is better tolerated by the body than that in the abdominal wall, potentially leading to fewer complications such as ileus, pain, adhesions, and hernias when compared with laparoscopic surgery.",
"     </li>",
"     <li>",
"      Elimination of an external scar thereby leading to better cosmetic outcomes (which to some patients may be the most important advantage).",
"     </li>",
"     <li>",
"      Better access to certain areas in the peritoneal cavity or in certain patients, such as those who are severely obese.",
"     </li>",
"     <li>",
"      The potential for shorter hospitalizations and reduced healthcare costs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evolution of laparoscopy was driven by patients, surgeons, and industry demand. A similar phenomenon may be evolving with NOTES. In a survey study of 100 patients considering laparoscopic cholecystectomy, 80 percent of respondents reported a theoretical preference for NOTES, based mainly upon the assumption that it would lead to less pain and fewer external scars [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/21\">",
"     21",
"    </a>",
"    ]. For those who preferred laparoscopic cholecystectomy, the most common reason was its proven safety and effectiveness. With regard to the choice of orifice used, both men and women preferred the mouth over the rectum or vagina. However, these outcomes were sensitive to the perceived risk. Thus, if the complication rate of NOTES was projected to double that of the laparoscopic approach, the preference for NOTES declined to 15 percent.",
"   </p>",
"   <p>",
"    However, these views are already evolving. A survey of 300 women revealed that at least three-fourths of them would not favor NOTES via a transvaginal approach over laparoscopic cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/22\">",
"     22",
"    </a>",
"    ]. A possible reason for this was that many of the women, especially younger nulliparous women, expressed concerned about future sexual function [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients in general may not fully understand the complexity of these approaches. Further, even with proper education and informed consent, opinion on the acceptability of the technique will also be influenced by cultural and geographic variations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TECHNICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the NOTES procedures in humans that have been performed have pushed the limits of currently available endoscopes and endoscopic accessories, leading to procedures that are far more complex, lengthy, and potentially riskier than they need to be. This is one reason why it is presently difficult, if not impossible, to directly compare laparoscopic and NOTES approaches. Fortunately, a number of platforms and tools are emerging that may render such studies feasible in the near future. Furthermore, even if they are not implemented for NOTES, these tools will help advance more conventional approaches, thus moving the whole field forward [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The key technical elements in a NOTES procedure are access via a hollow viscus, performance of the desired maneuver once in the target cavity, and closure of the port upon exit. Many technical variations have been described for gaining safe access to the peritoneal cavity via a hollow viscus such as the stomach, but it is now generally accepted that a minimal incision (eg, using a needle-knife or sphincterotome) followed by balloon dilation is preferred.",
"   </p>",
"   <p>",
"    Although the endoscope can be inserted directly through the newly created stoma, some form of overtube is generally used to allow multiple entries and complex maneuvers. Choosing which viscus to use for access is determined, at least in part, by the location of the target organ and the potential for visualization and appropriate triangulation to the target.",
"   </p>",
"   <p>",
"    As a general rule, the transgastric approach is best for lower abdominal and pelvic targets, whereas a transvaginal or transcolonic approach provides much straighter access to upper abdominal targets such as the gallbladder. This is important because many of the current instruments in use today are difficult to maneuver when the endoscope is retroflexed. When this general rule is not followed, spatial orientation during NOTES procedures can be very challenging to the surgeon. These technical constraints limit certain procedures to certain points of natural entry.",
"   </p>",
"   <p>",
"    Another major set of limitations stems from the design of the contemporary flexible endoscopes, which were not intended to serve as a platform for complex surgical techniques. They do not provide the rigidity and ability to triangulate that is desirable in most instances [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/24\">",
"     24",
"    </a>",
"    ]. Technological advances, however, have a tremendous potential to transform this platform and make it capable of much more sophisticated maneuvers.",
"   </p>",
"   <p>",
"    The final and perhaps most important technical challenge is to close the resultant viscerotomy in a secure, reliable, and safe manner. Indeed, a wider adoption of NOTES is critically dependent upon the safe and reliable closure of the viscerotomy and infection rates that are comparable if not better than conventional techniques. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Limitations'",
"    </a>",
"    below.) From this perspective, the transvaginal route is easier to secure after exit, although theoretical long-term consequences, such as dyspareunia and infertility, need to be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LIMITATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bacterial contamination, peritonitis, and abscess formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There will be some degree of bacterial contamination of the peritoneal cavity due to the viscerotomy and prolonged manipulation in the peritoneal cavity. A quantitative bacteriologic study in pigs showed a 20 to 40 percent incidence of abscesses and 40 to 60 percent incidence of significant contamination of the peritoneal fluid following NOTES, even in the absence of a leak [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/25\">",
"     25",
"    </a>",
"    ]. Although the abscesses were generally small, these studies suggest that bacterial infection is a potential threat that needs to be addressed carefully in clinical applications of NOTES.",
"   </p>",
"   <p>",
"    Thus far, in most clinical reports of natural orifice surgery, even though postoperative infections remain a great concern, there have been relatively few infections reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/19\">",
"     19",
"    </a>",
"    ]. A prevailing challenge is to develop an affordable, efficient, and high-level of disinfection or sterilization process for complex fiberoptic endoscopic systems such as those that are utilized in NOTES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Effects on the immune system and other physiological effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of animal models have been created to assess the physiologic, biochemical, and neurohormonal impact of NOTES access and manipulation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. One report found that circulating levels of cytokines such as IL1 beta, IL6, and TNF-alpha were similar in animals immediately following a sham operation, open exploration, laparoscopy, or transgastric NOTES [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/26\">",
"     26",
"    </a>",
"    ]. However, in the late postoperative period, there was a substantial decrease in TNF-alpha levels compared with the open and laparoscopic groups. The clinical significance of these observations remains unknown.",
"   </p>",
"   <p>",
"    Another concern with a NOTES procedure is the possibility of over-insufflation of the peritoneal cavity and subsequent decreased venous return to the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/29\">",
"     29",
"    </a>",
"    ]. Over-insufflation is prevented during laparoscopy by using pressure sensors, which are not currently available with standard endoscopy systems. There have been animal reports of successful monitoring of intra-abdominal pressures through the endoscope during NOTES; however, these findings have not been replicated in human studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/19,29\">",
"     19,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inability to deal with major complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major bleeding, laceration, perforation of neighboring organs, and other complications occur with any major abdominal surgery, whether it is done via NOTES or any other access. However, it would be far more difficult to rapidly address these complications with a NOTES approach, given the limited range of instruments available for use through the flexible endoscope. Such complications would in all likelihood require conversion to a laparoscopic or open approach.",
"   </p>",
"   <p>",
"    Complications have been reported to occur in 5.5 to 9.6 percent of procedures in different NOTES registries, with complications related to a transgastric approach being the most common [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/19\">",
"     19",
"    </a>",
"    ]. Reported complications include bleeding, bowel injury, biliary leaks, biliary fistulae, esophageal injury, and peritonitis. No mortality has been described, at least in the most current medical literature. Again, developments such as flexible endoscopic suturing devices may ameliorate some of these issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2359241173\">",
"    <span class=\"h2\">",
"     Training and credentialling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many surgeons are not comfortable using flexible endoscopic instruments as their use requires a very different set of manual skills, hand-eye coordination, and perception than what most surgeons were trained in. Although this situation is changing as surgery programs increase flexible endoscopy training, this issue will likely remain a major limitation to the rapid adoption of NOTES or NOTES-like procedures. At the same time, very few gastroenterologists have both the skill set and the inclination to enter the peritoneal cavity. Even if they do, it is unlikely that they will be given credentials to perform these procedures by either their institutions or national boards. Overcoming these challenges will require a large, concerted effort involving investigators and agencies overseeing training and credentialing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2359241189\">",
"    <span class=\"h2\">",
"     Economic limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The implementation of NOTES demands formidable financial resources above and beyond those required for technology development. NOTES procedures are generally far lengthier than laparoscopic procedures, but lack established reimbursement codes that can provide appropriate compensation for the effort involved [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/30\">",
"     30",
"    </a>",
"    ]. This may limit NOTES techniques mainly to academicians, as private practitioners may find the opportunity cost prohibitive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HUMAN EXPERIENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the inception of NOTES, several hundred human cases using NOTES have been reported and published, including 572 cases from a German registry and 362 cases from a Brazilian registry [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. However, only a handful of cases have been purely NOTES, requiring no laparoscopic instrumentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2359241197\">",
"    <span class=\"h2\">",
"     Transvaginal NOTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presently, the transvaginal NOTES approach has been the most common and successful. Vaginal surgery and organ retrieval through the vagina have been reported for many years and demand very little in terms of infrastructure and highly-trained expertise. Closure of the vaginal entry is far less complex than any other NOTES entry. Also, the flexible vaginal walls allow extraction of even large organs. Its relative safety makes this approach more attractive than many other NOTES approaches; however, it is an option in women and requires that gastrointestinal specialists enter the world of gynecological surgery.",
"   </p>",
"   <p>",
"    Most reports of transvaginal NOTES have utilized rigid instrumentation, either entirely or in addition to flexible endoscopy. There has been concern about the safety of using flexible endoscopy clips, especially for cholecystectomy. Such an argument has been the rationale for some to use conventional clips and, consequently, hybrid techniques.",
"   </p>",
"   <p>",
"    Transvaginal NOTES has been used for several operations other than cholecystectomy and appendectomy in humans. Other procedures have included sleeve gastrectomy, colon resections, and even abdominal wall hernia repair [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One account of the first 14 months of the German NOTES Registry reported a total of 572 target organs in 551 patients, of which cholecystectomy was the predominant operation (85 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/18\">",
"     18",
"    </a>",
"    ]. The approach used was a transvaginal hybrid procedure. Complications occurred in about 3 percent, with conversions to laparoscopy or open surgery in about 5 percent. The conversion rate was dependent upon institutional case volume, obesity, and age.",
"   </p>",
"   <p>",
"    Remaining challenges with this technique include potential dyspareunia, infertility, and a need to cannulate the bladder, which could potentially result in urinary infections, among the other potential complications previously described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2359241214\">",
"    <span class=\"h2\">",
"     Transgastric NOTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the transvaginal approach, entry through the stomach demands a much higher degree of technological sophistication, especially for closure. A growing number of devices have been created for this purpose. Most have been utilized only in animal or cadaver models, and their results have been increasingly promising. Thus far, closure of the gastric access site in human NOTES has required laparoscopic assistance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/19,31\">",
"     19,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Flexible endoscopic platforms are a must for this approach; however, all cases require some degree of hybridization. Procedures performed via a transgastric approach include appendectomy and cholecystectomy. Cancer staging and the retrieval of dislodged percutaneous endoscopic gastrostomy tubes have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The frequency and severity of complications with the transgastric route are higher than those experienced with the transvaginal approach. While the transgastric approach seems applicable to nearly all patients, only relatively small specimens may be conducive to extraction through the mouth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2359241231\">",
"    <span class=\"h2\">",
"     Miscellaneous approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hybrid NOTES techniques have been successfully implemented in transcolonic, transesophageal, and",
"    <span class=\"nowrap\">",
"     transurethral/transcystic",
"    </span>",
"    approaches. One novel technique that is not transluminal but involves entry through natural orifices is the management of achalasia by per oral endoscopic myotomy (POEM) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/34,35\">",
"     34,35",
"    </a>",
"    ] and over 50 cases have been successfully performed, of which at least 33 have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Advanced surgical procedures, such as sigmoidectomy for cancer, have been performed with a micro-assisted laparoscopy natural orifice surgery (MANOS) approach, but not yet using a true NOTES technique [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/16\">",
"     16",
"    </a>",
"    ]. Transanal endoscopic microsurgery has also been extended at times to transluminal resections [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     IMPLICATIONS BEYOND THE PROCEDURE ITSELF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even if NOTES procedures are not widely adopted, a major benefit may be to embolden endoscopists to be more aggressive even with intraluminal procedures, with the knowledge that limited perforation of the gut may have no ill effects, if repaired promptly. This will allow endoscopists to expand their therapeutic techniques to include resection of larger and deeper mucosal lesions, and to take full-thickness biopsies. A further benefit will come from the technological spin-offs from instrument development for NOTES. Many of these should be readily adaptable to intraluminal applications, enabling newer procedures. Finally, the advent of NOTES will have significant implications for the training of both gastroenterologists and surgeons, and has the potential for changing the way gastroenterology will be practiced in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2103/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some expert centers, natural orifice transluminal surgery (NOTES) is becoming an established alternative endoscopic and surgical technique. At such centers, some modified NOTES procedures are becoming routine under clinical trials (ie, Per Oral Endoscopic Myotomy [POEM] for achalasia). In most places, however, it continues evolving only in experimental models.",
"     </li>",
"     <li>",
"      Potential advantages of NOTES over conventional surgery are elimination or reduction of complications, such as surgical wound infections, abdominal wall hernias, and abdominal wall pain.",
"     </li>",
"     <li>",
"      Still, there is much more that needs to be learned about this procedure, including the risk of peritoneal contamination. So far, the available body of clinical experience does not demonstrate deleterious effects related to contamination and subsequent infection.",
"     </li>",
"     <li>",
"      At present, NOTES still should be considered primarily experimental and should be performed only in a research setting.",
"     </li>",
"     <li>",
"      Challenges for the scalable adoption of NOTES seem much more formidable and complex than once thought. However, some techniques are being implemented successfully in the clinical arena, even with basic endoscopic instrumentation (ie, POEM). NOTES research has resulted in the development of advanced surgical platforms that are applicable to endoscopic surgery and gastroenterology. This development promises to close a gap and to bring NOTES to a clinical reality in the near future.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/1\">",
"      Pasricha PJ. NOTES: a gastroenterologist's perspective. Gastrointest Endosc Clin N Am 2007; 17:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/2\">",
"      Kalloo AN, Singh VK, Jagannath SB, et al. Flexible transgastric peritoneoscopy: a novel approach to diagnostic and therapeutic interventions in the peritoneal cavity. Gastrointest Endosc 2004; 60:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/3\">",
"      Ryou M, Fong DG, Pai RD, et al. Dual-port distal pancreatectomy using a prototype endoscope and endoscopic stapler: a natural orifice transluminal endoscopic surgery (NOTES) survival study in a porcine model. Endoscopy 2007; 39:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/4\">",
"      Isariyawongse JP, McGee MF, Rosen MJ, et al. Pure natural orifice transluminal endoscopic surgery (NOTES) nephrectomy using standard laparoscopic instruments in the porcine model. J Endourol 2008; 22:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/5\">",
"      Kantsevoy SV, Hu B, Jagannath SB, et al. Transgastric endoscopic splenectomy: is it possible? Surg Endosc 2006; 20:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/6\">",
"      Sumiyama K, Gostout CJ, Rajan E, et al. Pilot study of transesophageal endoscopic epicardial coagulation by submucosal endoscopy with the mucosal flap safety valve technique (with videos). Gastrointest Endosc 2008; 67:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/7\">",
"      Fritscher-Ravens A, Patel K, Ghanbari A, et al. Natural orifice transluminal endoscopic surgery (NOTES) in the mediastinum: long-term survival animal experiments in transesophageal access, including minor surgical procedures. Endoscopy 2007; 39:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/8\">",
"      Giday SA, Buscaglia JM, Althaus J, et al. Successful diagnostic and therapeutic intrauterine fetal interventions by NOTES (abstract). Gastrointest Endosc 2008; 67:AB104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/9\">",
"      Magno P, Mas MA, Rivera Y, et al. NOTES Is Successful for vertebral spinal interventions with significant advantages for anterior spinal procedures (abstract). Gastrointest Endosc 2008; 67:AB114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/10\">",
"      Gill IS, Advincula AP, Aron M, et al. Consensus statement of the consortium for laparoendoscopic single-site surgery. Surg Endosc 2010; 24:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/11\">",
"      Curcillo PG 2nd, Wu AS, Podolsky ER, et al. Single-port-access (SPA) cholecystectomy: a multi-institutional report of the first 297 cases. Surg Endosc 2010; 24:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/12\">",
"      Rivas H, Varela E, Scott D. Single-incision laparoscopic cholecystectomy: initial evaluation of a large series of patients. Surg Endosc 2010; 24:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/13\">",
"      Ahmed, K, Wang, TT, Patel, VM, et, al. The role of single-incision laparaoscopic surgery in abdominal and pelvic surgery: a systematic review. Surg Endosc 2010; Jul 10:Epub ahead of print.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/14\">",
"      Antoniou SA, Pointner R, Granderath FA. Single-incision laparaoscopic cholecystectomy: a systematic review. Surg Endosc 2010; Jul 7: Epub ahead of print.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/15\">",
"      Cuschieri A. Minimal access surgery: the birth of a new era. J R Coll Surg Edinb 1990; 35:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/16\">",
"      Lacy AM, Delgado S, Rojas OA, et al. MA-NOS radical sigmoidectomy: report of a transvaginal resection in the human. Surg Endosc 2008; 22:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/17\">",
"      Zornig C, Mofid H, Siemssen L, et al. Transvaginal NOTES hybrid cholecystectomy: feasibility results in 68 cases with mid-term follow-up. Endoscopy 2009; 41:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/18\">",
"      Lehmann KS, Ritz JP, Wibmer A, et al. The German registry for natural orifice translumenal endoscopic surgery: report of the first 551 patients. Ann Surg 2010; 252:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/19\">",
"      Chukwumah C, Zorron R, Marks JM, Ponsky JL. Current status of natural orifice translumenal endoscopic surgery (NOTES). Curr Probl Surg 2010; 47:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/20\">",
"      Swain P. A justification for NOTES--natural orifice translumenal endosurgery. Gastrointest Endosc 2007; 65:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/21\">",
"      Varadarajulu S, Tamhane A, Drelichman ER. Patient perception of natural orifice transluminal endoscopic surgery as a technique for cholecystectomy. Gastrointest Endosc 2008; 67:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/22\">",
"      Strickland AD, Norwood MG, Behnia-Willison F, et al. Transvaginal natural orifice translumenal endoscopic surgery (NOTES): a survey of women's views on a new technique. Surg Endosc 2010; 24:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/23\">",
"      Mummadi RR, Pasricha PJ. The eagle or the snake: platforms for NOTES and radical endoscopic therapy. Gastrointest Endosc Clin N Am 2008; 18:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/24\">",
"      Pasricha PJ. The future of therapeutic endoscopy. Clin Gastroenterol Hepatol 2004; 2:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/25\">",
"      McGee MF, Marks JM, Onders RP, et al. Infectious implications in the porcine model of natural orifice transluminal endoscopic surgery (NOTES) with PEG-tube closure: a quantitative bacteriologic study. Gastrointest Endosc 2008; 68:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/26\">",
"      McGee MF, Schomisch SJ, Marks JM, et al. Late phase TNF-alpha depression in natural orifice translumenal endoscopic surgery (NOTES) peritoneoscopy. Surgery 2008; 143:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/27\">",
"      Bingener J, Michalek J, Van Sickle K, Schwesinger W. Randomized blinded trial shows relative thrombocytopenia in natural orifice translumenal endoscopic surgery compared with standard laparoscopy in a porcine survival model. Surg Endosc 2008; 22:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/28\">",
"      Bingener J, Michalek J, Winston J, et al. Randomized blinded trial comparing the cardiopulmonary effects of NOTES with standard laparoscopy in a porcine survival model. Surg Endosc 2008; 22:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/29\">",
"      McGee MF, Rosen MJ, Marks J, et al. A reliable method for monitoring intraabdominal pressure during natural orifice translumenal endoscopic surgery. Surg Endosc 2007; 21:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/30\">",
"      Maiss J, Zopf Y, Hahn EG. Entrance barriers and integration obstacles of NOTES. Minim Invasive Ther Allied Technol 2010; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/31\">",
"      Nikfarjam M, McGee MF, Trunzo JA, et al. Transgastric natural-orifice transluminal endoscopic surgery peritoneoscopy in humans: a pilot study in efficacy and gastrotomy site selection by using a hybrid technique. Gastrointest Endosc 2010; 72:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/32\">",
"      Marks JM, Ponsky JL, Pearl JP, McGee MF. PEG \"Rescue\": a practical NOTES technique. Surg Endosc 2007; 21:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/33\">",
"      Zorr&oacute;n R, Soldan M, Filgueiras M, et al. NOTES: transvaginal for cancer diagnostic staging: preliminary clinical application. Surg Innov 2008; 15:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/34\">",
"      Pasricha PJ, Hawari R, Ahmed I, et al. Submucosal endoscopic esophageal myotomy: a novel experimental approach for the treatment of achalasia. Endoscopy 2007; 39:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/35\">",
"      von Renteln D, Inoue H, Minami H, et al. Peroral endoscopic myotomy for the treatment of achalasia: a prospective single center study. Am J Gastroenterol 2012; 107:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/36\">",
"      Inoue H, Minami H, Kobayashi Y, et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 2010; 42:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/37\">",
"      Burghardt J, Buess G. Transanal endoscopic microsurgery (TEM): a new technique and development during a time period of 20 years. Surg Technol Int 2005; 14:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2103/abstract/38\">",
"      Jay Pasricha P, Krummel TM. NOTES and other emerging trends in gastrointestinal endoscopy and surgery: the change that we need and the change that is real. Am J Gastroenterol 2009; 104:2384.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2654 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2103=[""].join("\n");
var outline_f2_3_2103=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXPERIMENTAL EVOLUTION AND DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREMISE AND PROMISE OF NOTES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TECHNICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LIMITATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bacterial contamination, peritonitis, and abscess formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Effects on the immune system and other physiological effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inability to deal with major complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2359241173\">",
"      Training and credentialling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2359241189\">",
"      Economic limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HUMAN EXPERIENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2359241197\">",
"      Transvaginal NOTES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2359241214\">",
"      Transgastric NOTES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2359241231\">",
"      Miscellaneous approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      IMPLICATIONS BEYOND THE PROCEDURE ITSELF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_3_2104="HIV-associated nephropathy (HIVAN)";
var content_f2_3_2104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   HIV-associated nephropathy (HIVAN)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/3/2104/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/3/2104/contributors\">",
"     Christina M Wyatt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/3/2104/contributors\">",
"     Paul E Klotman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/3/2104/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/3/2104/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/3/2104/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/3/2104/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/3/2104/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11947711\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection has been associated with both acute kidney injury (AKI) and chronic kidney disease (CKD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=see_link\">",
"     \"Overview of kidney disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV-associated nephropathy (HIVAN), the classic kidney disease associated with HIV infection, was first described in 1984 as a complication of AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], although HIVAN may also occur in patients with less advanced HIV infection or acute seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Histologically, HIVAN is a collapsing form of focal sclerosing glomerulosclerosis (FSGS), which can be distinguished from idiopathic FSGS by the presence of microcystic tubular dilatation and interstitial inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to HIVAN will be discussed in this topic. An overview of kidney disease in patients with HIV infection and discussions of electrolyte abnormalities, dialysis, and transplantation in HIV-infected patients are provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=see_link\">",
"     \"Overview of kidney disease in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39332?source=see_link\">",
"     \"Electrolyte disturbances with HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34344?source=see_link\">",
"     \"Human immunodeficiency virus and dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15321?source=see_link\">",
"     \"Solid organ transplantation in HIV-infected individuals\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5577733\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of HIV-associated nephropathy (HIVAN) is hypothesized to involve several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection of kidney epithelial cells by HIV and expression of HIV genes within infected kidney cells",
"     </li>",
"     <li>",
"      Host factors, including genetic susceptibility",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Much of our current understanding of the pathogenesis of HIVAN has been derived from animal models, in particular the Tg26 HIV-1 transgenic mouse model [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/7\">",
"     7",
"    </a>",
"    ]. This transgenic mouse model expresses a",
"    <span class=\"nowrap\">",
"     gag/pol-deleted",
"    </span>",
"    HIV-1 provirus in kidney and develops proteinuria, renal failure, and histologic findings resembling human HIVAN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Following the reciprocal transplantation of kidneys between transgenic and wild-type mice, kidney disease develops only in kidneys donated by transgenic animals, suggesting that HIV gene expression in kidney cells is required for the development of HIVAN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/9\">",
"     9",
"    </a>",
"    ]. Transgenic mouse models suggest that certain HIV genes, such as Nef and Vpr, are specifically involved in the pathogenesis of HIVAN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/10-13\">",
"     10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV directly infects glomerular and renal tubular epithelial cells in humans with HIVAN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In addition, in vitro experiments have shown that HIV transgene expression induces glomerular epithelial cell dedifferentiation and proliferation.",
"   </p>",
"   <p>",
"    The strong association between HIVAN and black race indicates that host genetic factors are also important. Human genetic studies have identified single-nucleotide polymorphisms in the APOL1 gene (on chromosome 22) that are strongly linked to increased risk of HIVAN as well as idiopathic focal sclerosing glomerulosclerosis (FSGS) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. However, these variants, which are present almost exclusively in black individuals, do not appear to be associated with the severity of disease among those with biopsy-proven HIVAN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=see_link&amp;anchor=H1626413#H1626413\">",
"     \"Epidemiology of chronic kidney disease\", section on 'APOL1 in African Americans'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H9804961#H9804961\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'FSGS in African Americans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several other genes have been identified based upon differential expression in HIVAN, although their role in pathogenesis has not been elucidated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Breeding the Tg26 transgenic mouse onto different genetic backgrounds resulted in varying severity of kidney disease. Genetic studies in this model resulted in the identification of a susceptibility locus on chromosome 3, a genetic region that has been linked to other kidney diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5577956\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-associated nephropathy (HIVAN) displays a striking racial predilection for HIV-infected blacks and is more closely associated with black race than any other cause of end-stage renal disease (ESRD) except sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/24\">",
"     24",
"    </a>",
"    ]. Data from the US Renal Data System (USRDS) identify HIVAN as a leading cause of ESRD in young African-American adults [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The introduction of highly active antiretroviral therapy (HAART) has reduced the proportion of HIV-infected patients who develop ESRD attributed to HIVAN, although the absolute number of cases is expected to increase with the increasing prevalence of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/26\">",
"     26",
"    </a>",
"    ]. In a large urban cohort study, for example, the incidence of clinical or biopsy-proven HIVAN declined following the introduction of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/27\">",
"     27",
"    </a>",
"    ]. Data from the USRDS demonstrate a plateau in the annual incidence of ESRD attributed to HIVAN, with approximately 900 new cases each year [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/25\">",
"     25",
"    </a>",
"    ]. With improvements in survival, the number of patients living with ESRD attributed to HIVAN continues to increase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11947718\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HIV-associated nephropathy (HIVAN), the following features are usually present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Black race",
"      </strong>",
"      &ndash; In studies of adult and pediatric patients with HIVAN, 96 to 100 percent were of African descent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/28-31\">",
"       28-31",
"      </a>",
"      ]. According to data from the US Renal Data System (USRDS), approximately 90 percent of new end-stage renal disease (ESRD) cases attributed to HIVAN occur in African-Americans.",
"     </li>",
"     <li>",
"      <strong>",
"       Advanced HIV disease",
"      </strong>",
"      &ndash; In a study of 57 patients with proven HIVAN, about half of whom were taking highly active antiretroviral therapy (HAART), the mean HIV viral load was greater than 30,000",
"      <span class=\"nowrap\">",
"       copies/mL,",
"      </span>",
"      and the mean CD4 cell count was 127",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      (64 percent had a CD4 count less than 200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/30\">",
"       30",
"      </a>",
"      ]. In two other studies, 81 and 90 percent of patients who presented with HIVAN had CD4 positive T-cell counts less than 200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. It is apparent from these studies that HIVAN can present in patients with less advanced HIV infection. In addition, HIVAN has been reported in patients with acute HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Heavy (nephrotic-range) proteinuria",
"      </strong>",
"      &ndash; In a study of 71 children with HIVAN, 72 percent had nephrotic-range proteinuria at the time of presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/31\">",
"       31",
"      </a>",
"      ]. Studies in adults had similar findings [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. Among 57 patients with HIVAN, for example, mean proteinuria was 4.1",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      and only 14 percent of patients had proteinuria less than 1.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Rapid decline in kidney function",
"      </strong>",
"      &ndash; At the time of HIVAN diagnosis, adult patients often have advanced renal dysfunction, which is attributed to the rapidly progressive course. In two adult studies of patients with HIVAN, the mean estimated glomerular filtration rates (eGFR) at the time of renal diagnosis were, respectively, 10 and 20",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Children may not have similarly severe renal dysfunction at the time of presentation, although this may be a result of ascertainment bias rather than a true difference in the disease course. Among 71 South African children diagnosed with HIVAN, for example, only one-third had an eGFR less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other manifestations, such as hematuria, hypertension, and edema, may also be present, although the frequency of hypertension and edema are lower than may be expected in patients with severe proteinuria and renal dysfunction. In three studies of adult and pediatric patients with HIVAN, the following characteristics were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematuria (45 to 75 percent)",
"     </li>",
"     <li>",
"      Hypertension (12 to 26 percent)",
"     </li>",
"     <li>",
"      Edema (22 to 59 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11947725\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient suspected of having HIV-associated nephropathy (HIVAN) based upon clinical manifestations, the diagnosis must be established by a kidney biopsy. Nearly 40 percent of patients suspected of having HIVAN on clinical grounds will have an alternative histologic diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5578907\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIVAN is characterized by the collapsing form of focal segmental glomerulosclerosis (FSGS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Collapsing variant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to collapsing FSGS, HIVAN is typically characterized by dilated tubules and significant interstitial inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/24\">",
"     24",
"    </a>",
"    ]. While this unique histologic pattern was initially considered pathognomonic for HIVAN, virtually indistinguishable findings have been reported in patients treated with bisphosphonates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43512?source=see_link&amp;anchor=H5#H5\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\", section on 'Bisphosphonates and other drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The glomerular lesion of HIVAN is also characterized by dedifferentiation and proliferation of glomerular epithelial cells, which are typically considered terminally differentiated cells. This can be demonstrated by loss of maturity markers such as synaptopodin and expression of the cell-cycle protein Ki-67 in glomerular epithelial cells from animal models and patients with HIVAN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5578915\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, nearly 40 percent of patients suspected of having HIVAN based upon the clinical presentation will actually have a different histologic diagnosis. Alternative etiologies of kidney disease are common even in HIV-infected blacks presenting with nephrotic-range proteinuria. As an example, in a study of 107 HIV-infected black patients with proteinuria greater than 3",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    kidney biopsy revealed the following [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/34\">",
"     34",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HIVAN (56 percent)",
"     </li>",
"     <li>",
"      Classic FSGS (21 percent)",
"     </li>",
"     <li>",
"      Membranoproliferative glomerulonephritis (6 percent)",
"     </li>",
"     <li>",
"      Amyloidosis (4 percent)",
"     </li>",
"     <li>",
"      Diabetic nephropathy (4 percent)",
"     </li>",
"     <li>",
"      Lupus-like immune complex glomerulonephritis (4 percent)",
"     </li>",
"     <li>",
"      Other (5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This and other studies illustrate the importance of obtaining a kidney biopsy before making a diagnosis of HIVAN. The differential diagnosis in HIV-infected patients who present with renal dysfunction and proteinuria includes HIVAN and also the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune complex-mediated glomerulonephritis, including HIV immune complex kidney disease (HIVICK), IgA nephropathy, membranous nephropathy, membranoproliferative glomerulonephritis, membranous nephropathy, and a \"lupus-like\" proliferative glomerulonephritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=see_link&amp;anchor=H31719929#H31719929\">",
"       \"Overview of kidney disease in HIV-infected patients\", section on 'Immune complex mediated glomerulonephritis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glomerulonephritis due to coinfection with hepatitis C virus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=see_link&amp;anchor=H31719936#H31719936\">",
"       \"Overview of kidney disease in HIV-infected patients\", section on 'Glomerulonephritis due to hepatitis C virus coinfection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Amyloidosis, diabetic nephropathy, or other noninfectious glomerulopathies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11947739\">",
"    <span class=\"h1\">",
"     TREATMENT AND FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5579037\">",
"    <span class=\"h2\">",
"     Overview of medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatments that have been examined for patients with HIV-associated nephropathy (HIVAN) include highly active antiretroviral therapy (HAART); inhibitors of the renin-angiotensin system, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs); and glucocorticoids. Our recommendations and suggestions pertaining to these potential therapies are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients diagnosed with HIVAN who are not already receiving HAART, we recommend initiation of HAART. Our stance is in agreement with the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/35\">",
"       35",
"      </a>",
"      ] and with the United States Department of Health and Human Services (HHS)",
"      <a class=\"external\" href=\"file://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines\">",
"       Guidelines",
"      </a>",
"      for Antiviral Agents in HIV-infected Adults and Adolescents.",
"     </li>",
"     <li>",
"      In proteinuric",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertensive patients with HIVAN, we suggest therapy with either an ACE inhibitor or ARB.",
"     </li>",
"     <li>",
"      In patients with HIVAN, we suggest not routinely treating with glucocorticoids. However, some experts use a trial of glucocorticoids in patients with progressive disease who are close to requiring renal replacement therapy despite optimal therapy with HAART and angiotensin inhibition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rationale for these recommendations and suggestions is presented in the ensuing sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5579079\">",
"    <span class=\"h3\">",
"     HAART and HIVAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals diagnosed with HIVAN will have a strong indication for highly active antiretroviral therapy (HAART) initiation based upon criteria other than kidney disease, such as a CD4 cell count less than 500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    The rationale for the recommendation to initiate HAART in such patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H26#H26\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'Treatment recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No randomized trials have specifically examined the effect of HAART in patients with HIVAN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/36\">",
"     36",
"    </a>",
"    ]. Thus, the literature suggesting benefit from HAART in HIVAN consists of low-quality observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/37-39\">",
"     37-39",
"    </a>",
"    ] as well as sporadic case reports of kidney function recovery after initiation of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In addition, data from the US Renal Data System (USRDS) suggest a benefit of HAART on the epidemiology of end-stage renal disease (ESRD) attributed to HIVAN.",
"   </p>",
"   <p>",
"    As an example, the association of HAART initiation with renal outcomes was analyzed in a retrospective cohort of 36 patients with biopsy-proven HIVAN who did not require dialysis at the time of kidney biopsy; 26 were treated with HAART, and 10 received no antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/38\">",
"     38",
"    </a>",
"    ]. Renal outcomes were significantly better among patients treated with HAART:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Median renal survival was significantly longer among those receiving HAART (18.4 versus 3.9 months). However, the mean serum creatinine at baseline was significantly lower in patients who received HAART (4.7 versus 7.8",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      and the finding that renal survival was longer with HAART was not adjusted for baseline renal function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Among patients treated with HAART within three months of biopsy, the risk of needing dialysis was lower if a complete virological response was achieved, although this was not significant (62.5 versus 81.1 percent among those with a partial virological response).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two other retrospective studies demonstrated improved renal outcomes with HAART among patients with HIVAN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/37,39\">",
"     37,39",
"    </a>",
"    ]. Neither study controlled for baseline predictors of renal function, and, in one study, HIVAN was defined clinically instead of pathologically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5579094\">",
"    <span class=\"h3\">",
"     Renin-angiotensin system inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of ACE inhibitors and ARBs have been extrapolated from rigorous studies in other glomerular diseases and from cohort studies in patients with HIVAN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/37,42-44\">",
"     37,42-44",
"    </a>",
"    ]. There are",
"    <strong>",
"     no",
"    </strong>",
"    randomized trials of renin-angiotensin system inhibitors in such patients.",
"   </p>",
"   <p>",
"    The following examples illustrate the range of findings in support of treating patients who have HIVAN with ACE inhibitors or ARBs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A short-term study of 11 non-nephrotic and 9 nephrotic patients with biopsy-proven HIVAN reported more favorable changes in serum creatinine and 24-hour urine protein excretion among patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16872?source=see_link\">",
"       fosinopril",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      as compared with untreated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/44\">",
"       44",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      During approximately six months of follow-up, the creatinine rose from 1.3 to 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      among treated patients, compared to a creatinine rise from 1 to 4.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      among untreated patients.",
"     </li>",
"     <li>",
"      During the same interval, the 24-hour protein excretion in patients given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16872?source=see_link\">",
"       fosinopril",
"      </a>",
"      changed from 1.6 to 1.2",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      compared to an increase from 0.8 to 8.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      among untreated patients. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A subsequent study demonstrated significantly longer renal survival for patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16872?source=see_link\">",
"       fosinopril",
"      </a>",
"      as compared with untreated patients, despite similar characteristics and renal function at baseline (median renal survival of 480 days for treated patients versus 146 days for untreated patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/43\">",
"       43",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The appropriate intensity of therapy with ACE inhibitors or ARBs is unknown. Both of the aforementioned studies employed a fixed, low-dose regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16872?source=see_link\">",
"     fosinopril",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    In the absence of additional data, it is reasonable to adopt the goals for blood pressure and proteinuria control used in other nondiabetic chronic kidney diseases (CKD) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      We recommend a proteinuria goal of less than 1000",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      We recommend a blood pressure of less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg in proteinuric patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5579102\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small, uncontrolled studies have suggested that glucocorticoid therapy may improve renal function and reduce proteinuria in patients with HIVAN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], although the biologic mechanism is not clear. These studies were conducted before or early in the HAART era, and adverse events were common. Thus, in the absence of additional data, we suggest",
"    <strong>",
"     not",
"    </strong>",
"    routinely using glucocorticoid therapy for the treatment of HIVAN. It is reasonable to consider the addition of glucocorticoids in patients with rapid progression despite therapy with HAART and angiotensin inhibition. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5579363\">",
"    <span class=\"h2\">",
"     Routine chronic kidney disease care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Care of patients with HIVAN should be shared with a nephrologist or someone with expertise in managing patients with kidney disease.",
"   </p>",
"   <p>",
"    Supportive therapy of HIVAN and other CKD in patients with HIV includes appropriate medication dose adjustment, enhanced monitoring for medication toxicity, and avoidance of potentially nephrotoxic medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=see_link\">",
"     \"Overview of kidney disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with HIVAN should have routine monitoring and care, including management of mineral metabolism and timely preparation for dialysis or transplantation, similar to patients with CKD who do not have HIV. The general care of such patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25524404\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis in patients with HIVAN is poor, even among those treated with HAART. Many such patients will develop ESRD. The following examples illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A French study examined the outcomes of 57 patients diagnosed with HIVAN, half of whom were already taking HAART at the time of diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/30\">",
"       30",
"      </a>",
"      ]. The other half initiated HAART within one month of the diagnosis of HIVAN. Most patients were also treated with inhibitors of the renin-angiotensin system. A total of 51 patients were followed for a median of approximately two years. During that time, 6 patients died, and 30 developed ESRD (71 percent of those followed had one of these two outcomes). Patients who were already taking HAART at the time of HIVAN diagnosis were more likely to develop ESRD, as were those who developed HIVAN despite complete virologic suppression.",
"     </li>",
"     <li>",
"      A British study followed 31 patients with biopsy-proven HIVAN for a median of four and a half years; HAART was initiated in 29 of the 31 patients within one month of HIVAN diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/47\">",
"       47",
"      </a>",
"      ]. ESRD developed in 15 of these 31 patients (48 percent). Virological suppression was achieved in approximately 70 percent of patients, with no difference among patients who did and did not subsequently develop ESRD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5579382\">",
"    <span class=\"h2\">",
"     Dialysis and transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis should be offered to patients with HIVAN who develop ESRD. Survival rates of patients with HIV on dialysis are now similar to rates among dialysis patients without HIV. In addition, there is no evidence favoring one dialysis modality over another. Specific issues related to HIV infection in dialysis patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34344?source=see_link\">",
"     \"Human immunodeficiency virus and dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transplantation is a viable option for patients with HIVAN and ESRD in the era of HAART. Patient and graft survival may be similar to non-HIV-infected, high-risk transplant recipients. Kidney transplantation in patients with HIV is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15321?source=see_link\">",
"     \"Solid organ transplantation in HIV-infected individuals\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5579022\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathogenesis of HIV-associated nephropathy (HIVAN) is hypothesized to involve both direct infection of kidney epithelial cells by HIV with subsequent expression of HIV genes and host factors, including genetic susceptibility. The strong associations of HIVAN with black race and APOL1 gene polymorphisms illustrate the importance of host genetic factors. (See",
"      <a class=\"local\" href=\"#H5577733\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIVAN is more closely associated with black race than any other cause of end-stage renal disease (ESRD) except sickle cell disease and is a leading cause of ESRD in young African-American adults. The introduction of highly active antiretroviral therapy (HAART) has reduced the proportion of HIV-infected patients who develop ESRD attributed to HIVAN, although the absolute number of cases is expected to increase with the increasing prevalence of HIV infection. (See",
"      <a class=\"local\" href=\"#H5577956\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with HIVAN, the following features are common (see",
"      <a class=\"local\" href=\"#H11947718\">",
"       'Clinical manifestations'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Black race",
"     </li>",
"     <li>",
"      Advanced HIV disease",
"     </li>",
"     <li>",
"      Heavy (nephrotic-range) proteinuria",
"     </li>",
"     <li>",
"      Rapid decline in kidney function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other manifestations, such as hematuria, hypertension, and edema, may also be present, although the frequency of hypertension and edema are lower than may be expected in patients with severe proteinuria and renal dysfunction. (See",
"      <a class=\"local\" href=\"#H11947718\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a patient suspected of having HIVAN based upon clinical manifestations, the diagnosis should be established by a kidney biopsy. Nearly 40 percent of patients suspected of having HIVAN on clinical grounds will have an alternative histologic diagnosis. (See",
"      <a class=\"local\" href=\"#H11947725\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5578915\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIVAN is characterized by the collapsing form of focal segmental glomerulosclerosis (FSGS). In addition to collapsing FSGS, HIVAN is typically characterized by dilated tubules and significant interstitial inflammation. (See",
"      <a class=\"local\" href=\"#H5578907\">",
"       'Histology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients diagnosed with HIVAN who are not already receiving HAART, we recommend initiation of HAART (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Most individuals diagnosed with HIVAN will have a strong indication for HAART initiation based upon criteria other than kidney disease, such as a CD4 cell count less than 500",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      Our stance is in agreement with the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2104/abstract/35\">",
"       35",
"      </a>",
"      ] and with the United States Department of Health and Human Services (HHS)",
"      <a class=\"external\" href=\"file://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines\">",
"       Guidelines",
"      </a>",
"      for Antiviral Agents in HIV-infected Adults and Adolescents. (See",
"      <a class=\"local\" href=\"#H5579037\">",
"       'Overview of medical therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5579079\">",
"       'HAART and HIVAN'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In proteinuric",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertensive patients with HIVAN, we suggest therapy with either an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5579037\">",
"       'Overview of medical therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5579094\">",
"       'Renin-angiotensin system inhibition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with HIVAN, we suggest not routinely treating with glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, some experts use a trial of glucocorticoids in patients with progressive disease despite optimal therapy with HAART and angiotensin inhibition. (See",
"      <a class=\"local\" href=\"#H5579037\">",
"       'Overview of medical therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5579102\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis in patients with HIVAN is poor, even among those treated with HAART. Many such patients will develop ESRD. (See",
"      <a class=\"local\" href=\"#H25524404\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dialysis should be offered to patients with HIVAN who develop ESRD. Survival rates of patients with HIV on dialysis are now similar to rates among dialysis patients without HIV. Transplantation is a viable option for patients with HIVAN and ESRD in the era of HAART. Patient and graft survival may be similar to non-HIV-infected, high-risk transplant recipients. (See",
"      <a class=\"local\" href=\"#H5579382\">",
"       'Dialysis and transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/1\">",
"      Gardenswartz MH, Lerner CW, Seligson GR, et al. Renal disease in patients with AIDS: a clinicopathologic study. Clin Nephrol 1984; 21:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/2\">",
"      Pardo V, Aldana M, Colton RM, et al. Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/3\">",
"      Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984; 310:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/4\">",
"      Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001; 344:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/5\">",
"      Levin ML, Palella F, Shah S, et al. Hiv-associated nephropathy occurring before HIV antibody seroconversion. Am J Kidney Dis 2001; 37:E39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/6\">",
"      Laurinavicius A, Hurwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int 1999; 56:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/7\">",
"      Dickie P, Felser J, Eckhaus M, et al. HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 1991; 185:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/8\">",
"      Kopp JB, Klotman ME, Adler SH, et al. Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci U S A 1992; 89:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/9\">",
"      Bruggeman LA, Dikman S, Meng C, et al. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 1997; 100:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/10\">",
"      Dickie P, Roberts A, Uwiera R, et al. Focal glomerulosclerosis in proviral and c-fms transgenic mice links Vpr expression to HIV-associated nephropathy. Virology 2004; 322:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/11\">",
"      Kajiyama W, Kopp JB, Marinos NJ, et al. Glomerulosclerosis and viral gene expression in HIV-transgenic mice: role of nef. Kidney Int 2000; 58:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/12\">",
"      Hanna Z, Kay DG, Rebai N, et al. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 1998; 95:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/13\">",
"      Husain M, Gusella GL, Klotman ME, et al. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 2002; 13:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/14\">",
"      Bruggeman LA, Ross MD, Tanji N, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000; 11:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/15\">",
"      Ross MJ, Bruggeman LA, Wilson PD, Klotman PE. Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J Am Soc Nephrol 2001; 12:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/16\">",
"      Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/17\">",
"      Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/18\">",
"      Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/19\">",
"      Papeta N, Kiryluk K, Patel A, et al. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 2011; 22:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/20\">",
"      Atta MG, Estrella MM, Kuperman M, et al. HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int 2012; 82:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/21\">",
"      Ross MD, Bruggeman LA, Hanss B, et al. Podocan, a novel small leucine-rich repeat protein expressed in the sclerotic glomerular lesion of experimental HIV-associated nephropathy. J Biol Chem 2003; 278:33248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/22\">",
"      Kaufman L, Hayashi K, Ross MJ, et al. Sidekick-1 is upregulated in glomeruli in HIV-associated nephropathy. J Am Soc Nephrol 2004; 15:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/23\">",
"      Gharavi AG, Ahmad T, Wong RD, et al. Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3. Proc Natl Acad Sci U S A 2004; 101:2488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/24\">",
"      Abbott KC, Hypolite I, Welch PG, Agodoa LY. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol 2001; 14:377.",
"     </a>",
"    </li>",
"    <li>",
"     US Renal Data System (USRDS): USRDS 2004 Annual Data Report: Atlas of End-stage Renal Disease in the United States. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/26\">",
"      Schwartz EJ, Szczech LA, Ross MJ, et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005; 16:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/27\">",
"      Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/28\">",
"      Williams DI, Williams DJ, Williams IG, et al. Presentation, pathology, and outcome of HIV associated renal disease in a specialist centre for HIV/AIDS. Sex Transm Infect 1998; 74:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/29\">",
"      Lescure FX, Flateau C, Pacanowski J, et al. HIV-associated kidney glomerular diseases: changes with time and HAART. Nephrol Dial Transplant 2012; 27:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/30\">",
"      Big&eacute; N, Lanternier F, Viard JP, et al. Presentation of HIV-associated nephropathy and outcome in HAART-treated patients. Nephrol Dial Transplant 2012; 27:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/31\">",
"      Ramsuran D, Bhimma R, Ramdial PK, et al. The spectrum of HIV-related nephropathy in children. Pediatr Nephrol 2012; 27:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/32\">",
"      D'Agati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 1998; 18:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/33\">",
"      Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999; 10:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/34\">",
"      Atta MG, Choi MJ, Longenecker JC, et al. Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am J Med 2005; 118:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/35\">",
"      KDIGO. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/36\">",
"      Yahaya I, Uthman OA, Uthman MM. Interventions for HIV-associated nephropathy. Cochrane Database Syst Rev 2013; 1:CD007183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/37\">",
"      Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/38\">",
"      Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006; 21:2809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/39\">",
"      Cosgrove CJ, Abu-Alfa AK, Perazella MA. Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy. Am J Med Sci 2002; 323:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/40\">",
"      Kirchner JT. Resolution of renal failure after initiation of HAART: 3 cases and a discussion of the literature. AIDS Read 2002; 12:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/41\">",
"      Scheurer D. Rapid reversal of renal failure after initiation of HAART: a case report. AIDS Read 2004; 14:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/42\">",
"      Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 1996; 28:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/43\">",
"      Wei A, Burns GC, Williams BA, et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 2003; 64:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/44\">",
"      Burns GC, Paul SK, Toth IR, Sivak SL. Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 1997; 8:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/45\">",
"      Eustace JA, Nuermberger E, Choi M, et al. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 2000; 58:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/46\">",
"      Smith MC, Austen JL, Carey JT, et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 1996; 101:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2104/abstract/47\">",
"      Post FA, Campbell LJ, Hamzah L, et al. Predictors of renal outcome in HIV-associated nephropathy. Clin Infect Dis 2008; 46:1282.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14026 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2104=[""].join("\n");
var outline_f2_3_2104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5579022\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11947711\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5577733\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5577956\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11947718\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11947725\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5578907\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5578915\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11947739\">",
"      TREATMENT AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5579037\">",
"      Overview of medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5579079\">",
"      - HAART and HIVAN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5579094\">",
"      - Renin-angiotensin system inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5579102\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5579363\">",
"      Routine chronic kidney disease care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25524404\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5579382\">",
"      Dialysis and transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5579022\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43512?source=related_link\">",
"      Collapsing focal segmental glomerulosclerosis not associated with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39332?source=related_link\">",
"      Electrolyte disturbances with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=related_link\">",
"      Epidemiology of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34344?source=related_link\">",
"      Human immunodeficiency virus and dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=related_link\">",
"      Overview of kidney disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15321?source=related_link\">",
"      Solid organ transplantation in HIV-infected individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_3_2105="Anxiety in schizophrenia";
var content_f2_3_2105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anxiety in schizophrenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/3/2105/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/3/2105/contributors\">",
"     Sam G Siris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/3/2105/contributors\">",
"     Raphael J Braga, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/3/2105/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/3/2105/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/3/2105/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/3/2105/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/3/2105/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 10, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H931451436\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety is frequently observed among patients with schizophrenia. Its presence can be conceptualized as a component of the presentation of schizophrenia itself &mdash; particularly during an acute psychotic episode &mdash; a result of an underlying organic condition, a medication side effect, or a symptom of a comorbid anxiety disorder.",
"   </p>",
"   <p>",
"    A thorough psychiatric examination, including a medical history and physical exam, and possibly intervention trials, may be needed to arrive at an accurate diagnosis. Treatment is based on this determination.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, diagnosis, and treatment of anxiety in patients with schizophrenia are discussed here. Anxiety disorders and schizophrenia as individual, non-comorbid conditions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=see_link\">",
"     \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931451443\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 52 studies with a total of 4,032 patients with a schizophrenia spectrum disorder found that 38.3 percent suffered from a comorbid anxiety disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/1\">",
"     1",
"    </a>",
"    ]. Schizophrenia spectrum disorders include schizophrenia, schizoaffective, schizophreniform and delusional disorders, and psychosis not otherwise specified. Mean prevalence rates were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Social anxiety disorder (social phobia) &mdash; 14.9 percent",
"     </li>",
"     <li>",
"      Post-traumatic stress disorder (PTSD) &mdash; 12.4 percent",
"     </li>",
"     <li>",
"      Obsessive compulsive disorder (OCD) &mdash; 12.1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disorder rates across studies were markedly heterogeneous, largely due to use of different samples, diagnostic tools, and symptom-rating instruments. Mean rates were higher than those found for anxiety disorders in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931451450\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known regarding the pathophysiology of anxiety in schizophrenia. Imaging and post-mortem studies suggest that dysregulation of the major neurotransmitters, such as dopamine, glutamate, and serotonin may contribute to the presence of anxiety symptoms in schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/2\">",
"     2",
"    </a>",
"    ]. Familial aggregation of obsessive compulsive associated disorders (ie, OCD, obsessive compulsive personality disorder, and schizophrenia with comorbid obsessive symptoms) has been reported, such that relatives of schizophrenia patients with OCD have higher rates of anxiety disorders than relatives of schizophrenia probands without OCD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/3\">",
"     3",
"    </a>",
"    ]. This provides support for the validity of the OCD as a discrete comorbid entity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, these findings are derived from small samples, and no comparable studies have been done for other anxiety disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931451457\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;anxiety&rdquo; can be used to describe several different mental phenomena: an affect, a symptom, or one of several syndromes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an affect, anxiety performs an important signal function, alerting a person to danger. An example is the anxiety that alerts a person to look both ways before crossing the street.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anxiety a person experiences is described as a symptom if it is unduly severe, occurs in the absence of a sufficient cause, or lasts longer than is reasonable. In these cases, the unpleasant aspect of the anxious feeling has crossed a threshold that may lead a person to complain about it.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several anxiety syndromes or disorders are seen in some patients with schizophrenia. The disorders and their clinical features are described below [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/6\">",
"       6",
"      </a>",
"      ]. Symptoms of each disorder occur to the degree of causing significant distress or impairment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Obsessive-compulsive disorder: Obsessions are persistent thoughts, ideas, or images that are perceived as senseless and intrusive; compulsions are urges or impulses for repetitive intentional, stereotyped behavior performed to alleviate the anxiety of the obsessions.",
"     </li>",
"     <li>",
"      Panic disorder: Sudden onset of intense apprehension, fear or terror accompanied by the abrupt development of specific affective, cognitive, and somatic symptoms (eg, palpitations, shortness of breath).",
"     </li>",
"     <li>",
"      Posttraumatic stress disorder: Intrusive thoughts, nightmares and flashbacks of past traumatic events, avoidance of reminders of trauma, hypervigilance, exaggerated startle response and sleep disturbance.",
"     </li>",
"     <li>",
"      Phobia disorder: Marked, irrational, and persistent fears of an object, activity, or situation, which is actively avoided or endured with intense anxiety or distress.",
"     </li>",
"     <li>",
"      Social anxiety disorder: Unreasonable fear of embarrassment and humiliation in social or performance situations, leading to avoidance or intense anxiety.",
"     </li>",
"     <li>",
"      Generalized anxiety disorder: excessive anxiety and worry, fatigue, muscle tension, memory loss,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      insomnia. These disorders are described in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=see_link&amp;anchor=H4#H4\">",
"       \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Clinical manifestations and diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link&amp;anchor=H10#H10\">",
"       \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link&amp;anchor=H191515165#H191515165\">",
"       \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=see_link\">",
"       \"Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"       \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198360940\">",
"    <span class=\"h2\">",
"     Relationship between schizophrenia and anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety can occur secondary to schizophrenia (as an integral part of the active psychotic process), as an independent co-occurring syndrome, or as part of the schizophrenia prodrome. An example of anxiety as a secondary symptom is anxiety induced by terrifying hallucinations and delusions of an acute psychosis. When anxiety is secondary to psychosis, it tends to improve as psychosis improves, eg, in response to treatment.",
"   </p>",
"   <p>",
"    Epidemiologic research supports a conceptualization of anxiety syndromes (or disorders) as independent of co-occurring schizophrenia. High levels of anxiety symptoms or the presence of an anxiety disorder have been associated with more severe positive symptoms of schizophrenia, social withdrawal, depression, hopelessness, increased suicide rates, and poorer functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Patients with anxiety predating schizophrenia, or persisting in the absence of psychosis, have been shown to have a worse outcome than patients with anxiety that develops as a part of the psychotic process [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relationships between specific anxiety syndromes and particular components of psychotic psychopathology have been a subject of speculation. Examples follow:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Panic and paranoia both involve extreme states of fear. It has been proposed that the affective storm of anxiety during a panic attack can spur a patient with schizophrenia to scan his or her environment for danger that would justify the anxiety [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/9\">",
"       9",
"      </a>",
"      ]. A paranoid individual may experience an exaggerated perception of danger in his or her environment as a complement to the extreme anxiety of the panic attack.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obsessions in OCD can overlap conceptually with delusions in schizophrenia. It can be the inability of a patient to get a delusional thought off his or her mind, rather than the incorrectness of the thought, that causes much of the patient&rsquo;s suffering and functional impairment [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anxiety is often a feature in the prodrome leading to an episode of schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/11\">",
"     11",
"    </a>",
"    ]. Studies suggest that individuals with an early age of schizophrenia onset have a higher prevalence of anxiety than individuals with later onset. An analysis of data from the Epidemiologic Catchment Area study found that the presence of OCD, social phobia, or panic attacks were associated with a 2.6 to 3.5 increased odds of developing schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/12\">",
"     12",
"    </a>",
"    ]. The presence of anxiety disorders in patients with first episode psychosis has been associated with poorer initial outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931451471\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A challenge faced by a clinician evaluating anxiety in schizophrenia is determining the cause of the presentation. Essentially, the clinician must determine if the anxiety should be addressed as a constituent of schizophrenia, as a product of an underlying medical condition, a medication side effect, an understandable psychological reaction to transpiring events, or as an essentially distinct, co-occurring syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H921245\">",
"    <span class=\"h2\">",
"     Organic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many medical conditions can generate or mimic anxiety symptoms in patients with schizophrenia, including current medical illnesses, medication side effects, and substance abuse, dependence, or withdrawal. See tables for medical conditions and medications that can cause anxiety. &nbsp;The tables describe medical conditions and medication side effects that can cause or be mistaken for anxiety (",
"    <a class=\"graphic graphic_table graphicRef58758 \" href=\"UTD.htm?10/16/10508\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54521 \" href=\"UTD.htm?1/61/2013\">",
"     table 2",
"    </a>",
"    ). Individuals with schizophrenia have higher rates than the general population of several of these conditions, eg, cardiovascular and pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/15\">",
"     15",
"    </a>",
"    ] and substance use disorders including alcohol and nicotine abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=see_link\">",
"     \"Dual diagnosis: Severe mental illness and substance use disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=see_link\">",
"     \"Opioid detoxification during treatment for addiction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link\">",
"     \"Opioid withdrawal in the emergency setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link\">",
"     \"Benzodiazepine poisoning and withdrawal\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=see_link\">",
"     \"Ambulatory alcohol detoxification\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10099996\">",
"    <span class=\"h2\">",
"     Side effects of antipsychotics",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H920856\">",
"    <span class=\"h3\">",
"     Akathisia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common side effects of antipsychotic medications include anxiety and anxiety-like symptoms. Akathisia may present with fidgetiness and marked internal angst akin to that reported in primary anxiety. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link&amp;anchor=H272233794#H272233794\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524651#H76524651\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H920864\">",
"    <span class=\"h3\">",
"     Obsessions and compulsions",
"    </span>",
"    &nbsp;&mdash;&nbsp;De novo obsessive and compulsive symptoms can accompany initiation of a second-generation antipsychotic drug [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/18\">",
"     18",
"    </a>",
"    ]. Data suggest that the symptoms increase with antipsychotic dose. A temporal association between medication initiation (or dosage increase) and symptom onset can help to identify these side effects. However, the symptoms may develop weeks or months after medication initiation. The side effects are thought to be caused by the 5-HT2a antagonism of most second-generation antipsychotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100005\">",
"    <span class=\"h2\">",
"     Symptoms of schizophrenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phenomenological distinction between symptoms of anxiety disorders and psychotic symptoms can be often difficult to determine. During acute psychotic breaks it can be close to impossible. Examples of diagnostic challenges follow:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of schizophrenia involving fearfulness or having &ldquo;bad thoughts&rdquo; can mimic core features of agoraphobia, panic disorder, and OCD.",
"     </li>",
"     <li>",
"      The avoidance inherent in social anxiety can overlap phenomenologically with negative symptoms of schizophrenia (eg, a lack of interest in social activities).",
"     </li>",
"     <li>",
"      Obsessions in OCD can overlap with delusions in schizophrenia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/10\">",
"       10",
"      </a>",
"      ]. It can be the inability of a psychotic patient to get delusional thoughts off his or her mind, rather than the content of the thought itself, that causes much of the patient&rsquo;s suffering and functional impairment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10100012\">",
"    <span class=\"h2\">",
"     Anxiety disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comorbid anxiety disorder in patients with schizophrenia is a diagnosis of exclusion, diagnosed if the patient fully meets diagnostic criteria for the disorder from the DSM-IV-TR and if the alternative diagnostic possibilities described above have been ruled out [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/6\">",
"     6",
"    </a>",
"    ]. The individual anxiety disorders include OCD, PTSD, GAD, panic disorder, social anxiety disorder, or other phobic disorders. Diagnostic criteria for these disorders are provided in the tables (",
"    <a class=\"graphic graphic_table graphicRef55612 \" href=\"UTD.htm?28/54/29547\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73966 \" href=\"UTD.htm?37/9/38044\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57500 \" href=\"UTD.htm?8/55/9085\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78513 \" href=\"UTD.htm?15/1/15387\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60703 \" href=\"UTD.htm?21/15/21755\">",
"     table 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66613 \" href=\"UTD.htm?33/15/34043\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81555 \" href=\"UTD.htm?38/54/39787\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60377 \" href=\"UTD.htm?21/41/22171\">",
"     table 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link&amp;anchor=H13#H13\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=see_link&amp;anchor=H4#H4\">",
"     \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Clinical manifestations and diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931451486\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with schizophrenia presenting with anxiety, the assessment and treatment of the anxiety are closely intertwined. Thus, assessment and treatment are often performed in tandem, guided by the differential diagnosis. (See",
"    <a class=\"local\" href=\"#H931451471\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Assessment of anxiety can prove daunting when attempted in a single cross-sectional evaluation. It often requires meticulous history taking and clinical examination, optimally over an extended period. In addition, clinical interventions can be used to identify or rule out possible diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H920744\">",
"    <span class=\"h2\">",
"     Organic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A medical history, physical exam, review of the patient&rsquo;s medications and adherence, and laboratory testing are indicated to identify organic factors contributing to anxiety in patients with schizophrenia. A reasonable initial screening evaluation should include complete blood count, complete metabolic panel including free calcium and thyroid function tests. Cardiac conditions can be ruled out using an electrocardiogram or 24-hour cardiac monitoring. If pheochromocytoma is suspected, a 24-hr urine sample should be collected. &nbsp;",
"   </p>",
"   <p>",
"    Medical diseases, substance use disorders, and medications that cause anxiety symptoms are described under differential diagnosis. (See",
"    <a class=\"local\" href=\"#H921245\">",
"     'Organic factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A short-term treatment to alleviate the distress caused by anxiety symptoms might be indicated while the underlying problem is being addressed. Usually low doses of a benzodiazepine (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    1 to 3",
"    <span class=\"nowrap\">",
"     m/d",
"    </span>",
"    orally divided into doses twice or three times daily) are sufficient. The necessity for an anti-anxiety medication should be continuously reassessed as the medical condition is being treated.",
"   </p>",
"   <p>",
"    Anxiety symptoms can be due to substance misuse or withdrawal. The substance causing the symptoms should be discontinued and withdrawal symptoms, if present, promptly addressed. In the case of substance dependence or abuse causing anxiety, the substance-related disorder should be vigorously treated prior to, or in conjunction with, treatment of anxiety. For these patients, antidepressants are usually favored over benzodiazepines as first-line agents, due to the abuse potential of benzodiazepines. Most commonly used options are SSRIs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    50 to 200 mg orally daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    20 to 50 mg orally daily, or SNRIs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    75 to 225 mg orally daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H920751\">",
"    <span class=\"h2\">",
"     Antipsychotic side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line treatment for akathisia would be a decrease in the dose of the antipsychotic, if this can be done without exacerbating the psychotic disorder. If not feasible or ineffective, alternatives would be to change the antipsychotic to one less likely to cause akathisia, for instance switching from an FGA to a SGA, or switching to a less potent D2 blocker, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    . Other treatment options are to add a beta-blocker (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    20 to 40",
"    <span class=\"nowrap\">",
"     m/d",
"    </span>",
"    in two divided doses), benzodiazepine (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    1 to 3",
"    <span class=\"nowrap\">",
"     m/d",
"    </span>",
"    in two or three divided doses), or an adrenergic agonist (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    0.1 mg two or three times per day).",
"   </p>",
"   <p>",
"    In cases where the diagnosis is uncertain, a trial of one of these interventions may be helpful to identify or rule out akathisia. (See",
"    <a class=\"local\" href=\"#H10099996\">",
"     'Side effects of antipsychotics'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link&amp;anchor=H272233794#H272233794\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524651#H76524651\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial treatment of antipsychotic-induced obsessive and compulsive symptoms would be to decrease the antipsychotic medication, if this can be done without exacerbating the psychotic disorder. If this is not feasible or results in an inadequate response, the clinician should consider switching antipsychotics, possibly to one with less serotonin antagonism, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H824183832\">",
"    <span class=\"h3\">",
"     Clozapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A change in antipsychotic medication may not be an option when the patient is taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , because this drug is typically used in patients with schizophrenic symptoms refractory to other antipsychotics. Case reports have suggested that selective serotonin reuptake inhibitors (SSRI) may reduce clozapine-induced obsessive and compulsive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. However, it should be noted that controlled studies are lacking, and the risks of additional side effects should be weighed against potential benefits of adding an SSRI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some SSRIs (especially",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      ) interact with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      leading to toxic clozapine levels in some individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/22\">",
"       22",
"      </a>",
"      ]. Fluvoxamine should be avoided in patients receiving clozapine. Other SSRIs should be used with caution and accompanied by monitoring of clozapine drug levels. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"       \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H920968\">",
"    <span class=\"h2\">",
"     Symptoms of schizophrenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;To distinguish between anxiety as a symptom of schizophrenia and a distinct anxiety disorder, the clinician should be attuned to signs of temporal and clinical independence between the anxiety and psychotic symptoms. Examples follow:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a patient presenting with panic attacks, untriggered attacks are suggestive of a panic disorder, while panic accompanying the persecutory delusions of schizophrenia does not suggest an independent anxiety disorder.",
"     </li>",
"     <li>",
"      A patient avoiding social situations may have a comorbid social anxiety disorder, suggested by the presence of discomfort with social exposure, or may lack interest in social situations, a common negative symptom of schizophrenia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In many cases a single, cross-sectional evaluation will not be enough to achieve a correct diagnosis and repeated, longitudinal assessments of the clinical presentation may be needed. They would allow the clinician to determine, for example, whether the anxiety symptoms preceded or occurred independent of the psychotic symptoms.",
"   </p>",
"   <p>",
"    A diagnosis may not be attainable until after one or more trials of treatment. An example is a patient with an acute psychotic presentation, which often includes anxiety symptoms. Initiating an antipsychotic medication, or increasing an existing dose, is indicated to manage the psychotic syndrome; this will often be sufficient to treat the accompanying anxiety. This treatment response suggests that the anxiety was a symptom of schizophrenia.",
"   </p>",
"   <p>",
"    The presence of anxiety with an acute psychotic episode can increase the severity of the patient&rsquo;s status and the difficulty of clinical management. In these cases, suggested steps are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluate the level of environmental and intrapsychic stress to which the patient is exposed.",
"     </li>",
"     <li>",
"      In cases where specific situations or interpersonal interactions are identified as closely related to the onset of anxiety, the patient may benefit from supportive therapeutic techniques, building of the patient&rsquo;s coping skills, or family interventions. A single observational trial was conducted of a short-term psychoeducational intervention provided to 46 family members of inpatients treated for schizophrenia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/23\">",
"       23",
"      </a>",
"      ]. Significant reductions were seen in patient anxiety, family burden, and patient-family relationship difficulties. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8904?source=see_link\">",
"       \"Psychosocial interventions for schizophrenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If psychosocial interventions are not an option, due to availability or patient preference, acute treatment with benzodiazepines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      1 to 6",
"      <span class=\"nowrap\">",
"       m/d",
"      </span>",
"      orally in two to three divided doses) can be beneficial and safe. The need for the medication for anxiety should be re-evaluated once the psychotic exacerbation has improved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H920982\">",
"    <span class=\"h2\">",
"     Assessment for anxiety disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment for a comorbid anxiety disorder in schizophrenia includes ruling out other diagnostic possibilities and determining whether the patient meets DSM-IV-TR criteria for the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/6\">",
"     6",
"    </a>",
"    ]. While this may be clear cut in some cases, it may be more ambiguous in others. DSM-IV-TR criteria require that the current anxiety symptoms are &ldquo;not better accounted for by another mental disorder&rdquo;. This judgment is left to the individual clinician and may be less than obvious in some cases. Guidance for distinguishing anxiety disorders from anxiety as a symptom of schizophrenia is provided above. (See",
"    <a class=\"local\" href=\"#H920968\">",
"     'Symptoms of schizophrenia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H824184010\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatments for comorbid anxiety disorders have not been extensively studied in patients with schizophrenia. Large, randomized trials have not been conducted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H824183734\">",
"    <span class=\"h3\">",
"     Obsessive compulsive disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two small randomized trials have found the serotonergic antidepressants",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    to reduce obsessive compulsive disorder (OCD) symptoms in patients with schizophrenia compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/24\">",
"     24",
"    </a>",
"    ]. These findings have been supported by case reports suggesting efficacious treatment with similar agents:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , fluvoxamine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Due to the small amount of data from clinical trials of this population, clinicians could follow guidelines for treating OCD in the non-comorbid population. All five SSRIs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    are suggested as first line treatments. They should be started at low doses, eg, 5 to 10 mg of paroxetine or 25 mg of fluvoxamine. However, doses necessary to treat OCD are frequently higher than those needed to treat depression. A switch in medication or augmentation with another agent should be considered after 8 to 13 weeks of an initial adequate medication trial. It should be noted that SSRIs can result in potentially relevant changed in antipsychotics&rsquo; blood levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23561?source=see_link\">",
"     \"Pharmacotherapy for obsessive-compulsive disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trials and case reports have not reported adverse effects beyond what is typical in patients without schizophrenia. One case report described the apparent efficacy of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    in a patient unresponsive to oral clomipramine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/25\">",
"     25",
"    </a>",
"    ]. SSRIs should be used with caution concurrent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    and should be avoided with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H824183832\">",
"     'Clozapine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H824183782\">",
"    <span class=\"h3\">",
"     Panic attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports and open trials have reported reductions in panic attacks in patients with co-morbid schizophrenia and panic disorder treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Treatment of agoraphobia with diazepam was associated with improvement in one case report [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few case reports have suggested panic attacks respond to changes from a first to a second-generation antipsychotic [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. No studies were found of SSRIs for panic in schizophrenia. Because data on treatment of panic disorder in schizophrenia are sparse, clinicians should be guided by treatment recommendations for non-comorbid panic disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H824183894\">",
"    <span class=\"h3\">",
"     Social phobia",
"    </span>",
"    &nbsp;&mdash;&nbsp;One small, open trial suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    may be effective for patients with schizophrenia and social phobia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/32\">",
"     32",
"    </a>",
"    ]. Sixteen patients had their existing antipsychotics cross titrated with aripiprazole and were then followed for two months. The change to aripiprazole was associated with a reduction of social anxiety after three weeks of treatment. These results have not been replicated.",
"   </p>",
"   <p>",
"    Based on our clinical experience, we would advise use of SSRIs or SNRIs as first-line medication treatment for social phobia in schizophrenia based on a combination of efficacy and safety. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27416?source=see_link\">",
"     \"Pharmacotherapy for social anxiety disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H824183904\">",
"    <span class=\"h3\">",
"     Other anxiety disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;No published trials or case reports are available to evaluate the efficacy of pharmacotherapy for PTSD, GAD, or phobias other than social anxiety in patients with schizophrenia. We advise cautiously extrapolating the current treatment guidelines for these disorders in the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link\">",
"     \"Pharmacotherapy for generalized anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H824184063\">",
"    <span class=\"h2\">",
"     Cognitive behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with schizophrenia, cognitive behavioral therapy (CBT) has been found to be efficacious in a handful of small, mostly randomized trials for patients with panic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/33\">",
"     33",
"    </a>",
"    ], social anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], and PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. An example is a trial of 33 patients with schizophrenia and comorbid social anxiety randomly assigned to either group CBT or to a waiting list [",
"    <a class=\"abstract\" href=\"UTD.htm?2/3/2105/abstract/35\">",
"     35",
"    </a>",
"    ]. After 12 weekly sessions of group CBT, patients in the treatment group showed improvement in social anxiety and related symptoms compared to the control group. The efficacy of psychotherapies for anxiety disorders comorbid with schizophrenia requires more extensive study.",
"   </p>",
"   <p>",
"    Although not empirically tested in schizophrenia and varying by anxiety disorder, combined therapy with medication and CBT may be more effective than either of the individual modalities. However, in mild to moderate cases, psychotherapy with CBT would be a sensible first-line treatment strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link&amp;anchor=H5614762#H5614762\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\", section on 'Combining pharmacotherapy and psychotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32327?source=see_link&amp;anchor=H362076628#H362076628\">",
"     \"Psychotherapy for social anxiety disorder\", section on 'Combining CBT and medication'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931451493\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comorbid anxiety disorders are a common occurrence among patients with schizophrenia. Higher levels of anxiety are associated with more prominent positive symptoms of schizophrenia and poorer functioning. (See",
"      <a class=\"local\" href=\"#H931451443\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of anxiety in a patient with schizophrenia includes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Anxiety or anxiety-like symptoms due to a medical condition, medication, or substance use disorder",
"     </li>",
"     <li>",
"      Side effects of antipsychotic medications such as akathisia or",
"      <span class=\"nowrap\">",
"       obsessions/compulsions",
"      </span>",
"     </li>",
"     <li>",
"      Anxiety that is a component of schizophrenia",
"     </li>",
"     <li>",
"      An independent, comorbid anxiety disorder (See",
"      <a class=\"local\" href=\"#H931451471\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific anxiety disorders that can co-occur with schizophrenia include: (See",
"      <a class=\"local\" href=\"#H931451457\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Obsessive-compulsive disorder (OCD)",
"     </li>",
"     <li>",
"      Post-traumatic stress disorder (PTSD)",
"     </li>",
"     <li>",
"      Generalized anxiety disorder (GAD)",
"     </li>",
"     <li>",
"      Panic disorder",
"     </li>",
"     <li>",
"      Social anxiety disorder",
"     </li>",
"     <li>",
"      Phobic disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A medical history, physical exam, review of the patient&rsquo;s medications and adherence, and laboratory testing are indicated to identify organic factors contributing to anxiety in patients with schizophrenia. A basic screening evaluation should include complete blood count, complete metabolic panel and thyroid function tests, an electrocardiogram, and chest X-ray. (See",
"      <a class=\"local\" href=\"#H921245\">",
"       'Organic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is typically based on the diagnosis of anxiety:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A medical condition causing anxiety requires treatment of the underlying condition. A patient experiencing significant distress or impairment may benefit from short-term treatment with a low dose of a benzodiazepine (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      1 to 3",
"      <span class=\"nowrap\">",
"       m/d",
"      </span>",
"      orally divided into two to three divided doses). (See",
"      <a class=\"local\" href=\"#H920744\">",
"       'Organic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First-line treatment for akathisia is a reduction of the antipsychotic dose, if tolerated without worsening the patient&rsquo;s psychosis. Alternatives include changing the antipsychotic to one less likely to cause akathisia (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ) or treatment with a benzodiazepine (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      1 to 3",
"      <span class=\"nowrap\">",
"       m/d",
"      </span>",
"      orally in two to three divided doses) or beta-blocker (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      20 to 40 mg twice daily). (See",
"      <a class=\"local\" href=\"#H920751\">",
"       'Antipsychotic side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anxiety secondary to an acute psychotic episode typically improves with the antipsychotic drug used to treatment the psychosis. (See",
"      <a class=\"local\" href=\"#H920968\">",
"       'Symptoms of schizophrenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of comorbid anxiety disorders in patients with schizophrenia (See",
"      <a class=\"local\" href=\"#H824184010\">",
"       'Pharmacotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H824184063\">",
"       'Cognitive behavioral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with comorbid panic disorder, social anxiety disorder, or PTSD who do not respond adequately to medication, we suggest a trial of adjunctive CBT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). CBT is not always available and requires a patient with the ability to participate. (See",
"      <a class=\"local\" href=\"#H920982\">",
"       'Assessment for anxiety disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/1\">",
"      Achim AM, Maziade M, Raymond E, et al. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 2011; 37:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/2\">",
"      Muller JE, Koen L, Soraya S, et al. Anxiety disorders and schizophrenia. Curr Psychiatry Rep 2004; 6:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/3\">",
"      Poyurovsky M, Kriss V, Weisman G, et al. Familial aggregation of schizophrenia-spectrum disorders and obsessive-compulsive associated disorders in schizophrenia probands with and without OCD. Am J Med Genet B Neuropsychiatr Genet 2005; 133B:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/4\">",
"      Braga RJ, Mendlowicz MV, Marrocos RP, Figueira IL. Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life. J Psychiatr Res 2005; 39:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/5\">",
"      Lysaker PH, Salyers MP. Anxiety symptoms in schizophrenia spectrum disorders: associations with social function, positive and negative symptoms, hope and trauma history. Acta Psychiatr Scand 2007; 116:290.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th, text revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/7\">",
"      Fenton WS, McGlashan TH. The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 1986; 143:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/8\">",
"      Hwang MY, Morgan JE, Losconzcy MF. Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study. J Neuropsychiatry Clin Neurosci 2000; 12:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/9\">",
"      Bermanzohn PC, Arlow PB, Albert C, Siris SG. Relationship of panic attacks to paranoia. Am J Psychiatry 1999; 156:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/10\">",
"      Berman I, Merson A, Viegner B, et al. Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: a neuropsychological study. J Nerv Ment Dis 1998; 186:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/11\">",
"      Shioiri T, Shinada K, Kuwabara H, Someya T. Early prodromal symptoms and diagnoses before first psychotic episode in 219 inpatients with schizophrenia. Psychiatry Clin Neurosci 2007; 61:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/12\">",
"      Tien AY, Eaton WW. Psychopathologic precursors and sociodemographic risk factors for the schizophrenia syndrome. Arch Gen Psychiatry 1992; 49:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/13\">",
"      Strakowski SM, Tohen M, Stoll AL, et al. Comorbidity in psychosis at first hospitalization. Am J Psychiatry 1993; 150:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/14\">",
"      Craig T, Hwang MY, Bromet EJ. Obsessive-compulsive and panic symptoms in patients with first-admission psychosis. Am J Psychiatry 2002; 159:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/15\">",
"      Druss BG, Bradford WD, Rosenheck RA, et al. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001; 58:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/16\">",
"      Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 2002; 59:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/17\">",
"      de Leon J, Tracy J, McCann E, et al. Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital. Schizophr Res 2002; 56:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/18\">",
"      Kim SW, Shin IS, Kim JM, et al. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. Clin Neuropharmacol 2009; 32:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/19\">",
"      Allen L, Tejera C. Treatment of clozapine-induced obsessive-compulsive symptoms with sertraline. Am J Psychiatry 1994; 151:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/20\">",
"      Poyurovsky M, Hermesh H, Weizman A. Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients. Clin Neuropharmacol 1996; 19:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/21\">",
"      Rahman MS, Grace JJ, Pato MT, Priest B. Sertraline in the treatment of clozapine-induced obsessive-compulsive behavior. Am J Psychiatry 1998; 155:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/22\">",
"      Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996; 153:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/23\">",
"      Yamaguchi H, Takahashi A, Takano A, Kojima T. Direct effects of short-term psychoeducational intervention for relatives of patients with schizophrenia in Japan. Psychiatry Clin Neurosci 2006; 60:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/24\">",
"      Braga RJ, Petrides G, Figueira I. Anxiety disorders in schizophrenia. Compr Psychiatry 2004; 45:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/25\">",
"      Poyurovsky M, Weizman A. Intravenous clomipramine for a schizophrenic patient with obsessive-compulsive symptoms. Am J Psychiatry 1998; 155:993.",
"     </a>",
"    </li>",
"    <li>",
"     Figueira, I, Mendlowicz, M, Nardi, AE et al. Social phobia and panic disorder in psychotic patients: psychopharmacology series 6. J bras Psiq 1992; 41:259.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/27\">",
"      Kahn JP, Puertollano MA, Schane MD, Klein DF. Adjunctive alprazolam for schizophrenia with panic anxiety: clinical observation and pathogenetic implications. Am J Psychiatry 1988; 145:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/28\">",
"      Siris SG, Aronson A, Sellew AP. Imipramine-responsive panic-like symptomatology in schizophrenia/schizoaffective disorder. Biol Psychiatry 1989; 25:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/29\">",
"      Argyle N. Panic attacks in chronic schizophrenia. Br J Psychiatry 1990; 157:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/30\">",
"      Takahashi H, Higuchi H, Shimizu T. Full remission of panic attacks in a schizophrenic patient after switching from haloperidol to risperidone. J Neuropsychiatry Clin Neurosci 2001; 13:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/31\">",
"      Takahashi H, Sugita T, Yoshida K, et al. Effect of quetiapine in the treatment of panic attacks in patients with schizophrenia: 3 case reports. J Neuropsychiatry Clin Neurosci 2004; 16:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/32\">",
"      Stern RG, Petti TA, Bopp K, Tobia A. Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. J Clin Psychopharmacol 2009; 29:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/33\">",
"      Arlow PB, Moran ME, Bermanzohn PC, et al. Cognitive-behavioral treatment of panic attacks in chronic schizophrenia. J Psychother Pract Res 1997; 6:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/34\">",
"      Halperin S, Nathan P, Drummond P, Castle D. A cognitive-behavioural, group-based intervention for social anxiety in schizophrenia. Aust N Z J Psychiatry 2000; 34:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/35\">",
"      Kingsep P, Nathan P, Castle D. Cognitive behavioural group treatment for social anxiety in schizophrenia. Schizophr Res 2003; 63:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/36\">",
"      Mueser KT, Rosenberg SD, Xie H, et al. A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. J Consult Clin Psychol 2008; 76:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/3/2105/abstract/37\">",
"      Frueh BC, Grubaugh AL, Cusack KJ, et al. Exposure-based cognitive-behavioral treatment of PTSD in adults with schizophrenia or schizoaffective disorder: a pilot study. J Anxiety Disord 2009; 23:665.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15259 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-9685F97C73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2105=[""].join("\n");
var outline_f2_3_2105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H931451493\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931451436\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931451443\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931451450\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931451457\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H198360940\">",
"      Relationship between schizophrenia and anxiety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931451471\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H921245\">",
"      Organic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10099996\">",
"      Side effects of antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H920856\">",
"      - Akathisia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H920864\">",
"      - Obsessions and compulsions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10100005\">",
"      Symptoms of schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10100012\">",
"      Anxiety disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931451486\">",
"      ASSESSMENT AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H920744\">",
"      Organic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H920751\">",
"      Antipsychotic side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H824183832\">",
"      - Clozapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H920968\">",
"      Symptoms of schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H920982\">",
"      Assessment for anxiety disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H824184010\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H824183734\">",
"      - Obsessive compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H824183782\">",
"      - Panic attacks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H824183894\">",
"      - Social phobia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H824183904\">",
"      - Other anxiety disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H824184063\">",
"      Cognitive behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931451493\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/15259\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/15259|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/16/10508\" title=\"table 1\">",
"      Physical causes anxiety Sxs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/61/2013\" title=\"table 2\">",
"      Drugs causing anxiety Sxs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/54/29547\" title=\"table 3\">",
"      Dx criteria generalized anxiety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/9/38044\" title=\"table 4\">",
"      Dx criteria panic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/55/9085\" title=\"table 5\">",
"      Diagnosis posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/1/15387\" title=\"table 6\">",
"      Diagnostic criteria for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/15/21755\" title=\"table 7\">",
"      Dx criteria social phobia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/15/34043\" title=\"table 8\">",
"      DSM-IV-TR criteria for social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/54/39787\" title=\"table 9\">",
"      DSM-IV-TR criteria for specific phobia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/41/22171\" title=\"table 10\">",
"      DSM-IV-TR criteria for agoraphobia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=related_link\">",
"      Ambulatory alcohol detoxification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=related_link\">",
"      Dual diagnosis: Severe mental illness and substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=related_link\">",
"      Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=related_link\">",
"      Opioid detoxification during treatment for addiction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=related_link\">",
"      Opioid withdrawal in the emergency setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=related_link\">",
"      Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=related_link\">",
"      Pharmacotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23561?source=related_link\">",
"      Pharmacotherapy for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=related_link\">",
"      Pharmacotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27416?source=related_link\">",
"      Pharmacotherapy for social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8904?source=related_link\">",
"      Psychosocial interventions for schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32327?source=related_link\">",
"      Psychotherapy for social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=related_link\">",
"      Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=related_link\">",
"      Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_3_2106="Merkel cell carcinoma - face";
var content_f2_3_2106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50573%7EDERM%2F70535%7EONC%2F52988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50573%7EDERM%2F70535%7EONC%2F52988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Merkel cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This blue-red, dome-shaped papule on the forehead is a Merkel cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Merkel cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This blue-red, dome-shaped nodule is a Merkel cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Merkel cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large, eroded Merkel cell carcinoma nodule arising on the forearm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick, TB, Johnson, RA, Wolff, K, Suurmond, D. Color Atlas &amp; Synopsis of Clinical Dermatology. Common &amp; Serious Diseases. (4th Ed). McGraw-Hill, New York 2001. pgs. 268 &amp; 289. Copyright &copy; 2001 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2106=[""].join("\n");
var outline_f2_3_2106=null;
var title_f2_3_2107="Prevalence of body fold defects";
var content_f2_3_2107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of body fold defects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Defect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Omphalocele (simple)",
"       </td>",
"       <td>",
"        1/5500 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentalogy of Cantrell",
"       </td>",
"       <td>",
"        1/100,000 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cloacal exstrophy",
"       </td>",
"       <td>",
"        1/200,000 births",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Body stalk defect",
"       </td>",
"       <td>",
"        3/700,000 births",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2107=[""].join("\n");
var outline_f2_3_2107=null;
var title_f2_3_2108="Amino acids";
var content_f2_3_2108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Amino acids",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Nonessential",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alanine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arginine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Asparagine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aspartic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Citrulline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glutamic acid (glutamate)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glutamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glycine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Histidine*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Proline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Serine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tyrosine",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Essential",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isoleucine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leucine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lysine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methionine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenylalanine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Threonine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tryptophan",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Valine",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Essential for infants.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2108=[""].join("\n");
var outline_f2_3_2108=null;
var title_f2_3_2109="Education at 2nd follow up";
var content_f2_3_2109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Delivery of asthma education by clinicians during patient care visits: recommendations for second followup visit",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Assessment questions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Focus on:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Expectations of visit",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Goals of treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Quality of life",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Ask relevant questions from previous visit and also ask:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"Have you noticed anything in your home, work, or school that makes your asthma worse?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"Describe for me how you know when to call your doctor or go to the hospital for asthma care.\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What questions do you have about the action plan?\" \"Can we make it easier?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"Are your medications causing you any problems?\"",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Information",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach or review in simple language:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Relevant environmental control/avoidance strategies:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            How to identify home, work, or school exposures that can cause or worsen asthma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            How to control house-dust mites, animal exposure if applicable",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            How to avoid cigarette smoke (active and passive)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Review all medications.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Review and interpret from daily diary:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Peak flow measures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Symptom scores",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach or review and demonstrate:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inhaler/spacer/holding chamber technique.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Peak flow monitoring technique.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Use of daily self-management plan. Review and adjust as needed.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\" rowspan=\"5\">",
"            Review use of action plan. Confirm that patient knows what to do if asthma gets worse.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2109=[""].join("\n");
var outline_f2_3_2109=null;
var title_f2_3_2110="TMLR improves left ventricular myocardial perfusion";
var content_f2_3_2110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transmyocardial laser revascularization improves left ventricular myocardial perfusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 329px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The percentage change in myocardial perfusion is calculated as the number of defects at baseline minus the number of defects at follow-up, divided by the number of defects at baseline. Myocardial perfusion improved with transmyocardial laser revascularization (TMLR) but worsened with medical therapy; the percent change in myocardial perfusion differed significantly at each point in time of evaluation (p = 0.001 at three&nbsp;months, p = 0.02 at&nbsp;six months, and p = 0.002 at 12 months). At one year, myocardial perfusion improved by 20 percent in patients undergoing TMLR while is worsened by 27 percent in the medical treatment group.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Frazier OH, March RJ, Horvath KA. N Engl J Med 1999; 341:1021.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2110=[""].join("\n");
var outline_f2_3_2110=null;
var title_f2_3_2111="Microbes in odontogenic infx";
var content_f2_3_2111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Microbial specificity and odontogenic infections*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 464px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A unifying hypothesis demonstrating a microbial shift from a plaque-free tooth surface and progression to supragingival and subgingival organisms.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from Chow, AW. Odontogenic infections. In: Infections of the Head and Neck, Schlossberg, D (Ed), Springer-Verlag, New York 1987, p.149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_3_2111=[""].join("\n");
var outline_f2_3_2111=null;
